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ABSTRACT 
 
Transitions within opioid therapy and their impact on morbidity,  
healthcare utilization, and costs 
James Douglas Thornton 
 
 In the United States (US), chronic non-cancer pain (CNCP) is prevalent among adults 
with costs exceeding half a billion dollars annually1 and can be especially burdensome for 
working age adults due to lost productivity and negative impacts on quality of life.2-6 An 
estimated 43% of adults experience pain, and the majority of them are working age (22-64 
years).6 Despite lack of robust evidence on the efficacy and effectiveness of opioids relieving 
CNCP,7,8 and currently-available effective non-opioid treatments,9 many patients still receive 
opioid therapy. Opioids are associated with significant negative health consequences up to and 
including addiction to opioids which further increases their risk for overdose and death.10 
Effective clinical, policy, and community responses to solve the opioid epidemic focus on a 
continuum beginning with appropriate initiation of opioids and ending with harm reduction 
efforts.11-17 The first step is the appropriate initiation of opioids because as many as 46% of 
adults who were initiated on opioids transition into chronic opioid users.18 Chronic opioid 
therapy (COT) can exacerbate current conditions and lead to development of new chronic 
physical and mental health conditions, and other opioid-related adverse effects including 
overdose.7,19-22 These negative consequences related to opioids lead to high economic burden 
through increased emergency room, inpatient, and other healthcare utilization and healthcare 
expenditures.19-24 Analysis of COT and its economic burden is especially important among 
working-age adults who receive opioids more frequently when they experience pain.25  
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This study was conducted to (1) assess factors which predict the transition to COT, (2) 
estimate the changes in healthcare utilization and expenditure associated with the transition to 
COT, and (3) to identify educational strategies that can be used to fill knowledge gaps about 
opioids, naloxone, and opioid use disorder treatment medications for a group of healthcare 
professionals who are well suited to help alleviate the opioid epidemic.  
First, we identified leading predictors associated with incident COT among adults 
without cancer in the US using a 10% random sample of working-age adults (age 28-63 years) 
insured in commercial plans, who were initiated on opioids between January 2007 through May 
2015. The four leading predictors of COT were opioid duration-of-action [AOR= 12.28; 95%CI= 
8.06-18.72], parent opioid tramadol vs. codeine, [AOR= 7.26; 95%CI= 5.20-10.13], the presence 
of conditions highly likely to cause chronic pain [AOR= 5.47; 95%CI= 3.89-7.68] and drug use 
disorders [AOR= 4.02; 95%CI= 2.53-6.40]. Next, using the same data source, we assessed the 
association between transitioning from incident opioid use to chronic opioid therapy (COT), on 
the trajectories of health utilization and expenditures. Patients who transitioned to COT were 
more likely to use inpatient services [AOR=1.11, 95%CI(1.01,1.21)] compared to those who did 
not transition. While expenditures peaked during the transition period (t4) for all users, 
differences in unadjusted average, 120-day expenditures between COT and no COT users were 
highest in t4 for total ($4,607) and inpatient expenditures ($2,453). COT users had significantly 
higher total (β=0.183, p<0.01) and inpatient expenditures (β=0.448, p<0.001). For these first two 
aims, we found that initial opioid regimen characteristics are powerful predictors of COT, and 
the period after incident opioid prescription, but before COT, is an important time for 
intervention for payers.  
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Patients who have already transitioned to COT, or even opioid misuse or abuse need 
increased levels of care. The third aim sought to identify educational strategies related to opioids, 
buprenorphine products, and naloxone, for pharmacists, and to determine geographic locations to 
reduce the risk of opioid overdose in West Virginia (WV). A mixed-methods design included a 
prospective cross-sectional survey administered in two phases to increase coverage of the whole 
state, then results were weighted based on a census of all pharmacists in WV. Most pharmacists 
perceived high risk of opioid misuse in their area and high perceived efficacy about naloxone as 
a treatment for opioid overdose, but many did not feel comfortable selling naloxone. Opioid 
attitudes significantly differed between pharmacists in different EPPM-assigned categories. 
Filling practices differed; 73% stocked buprenorphine/naloxone and only 58% stocked 
buprenorphine. Pharmacists with higher perceived efficacy of buprenorphine products were more 
likely to be willing to fill non-local prescriptions. County-level disparities between actual and 
perceived risk for opioid misuse were observed. In the qualitative evaluation, pharmacists listed 
many barriers to caring for patients prescribed opioids or buprenorphine products. By tailoring 
educational strategies and objectives to pharmacists in specific geographic locations, more 
effective CPE can be delivered to community pharmacists in WV to improve access to naloxone 
and buprenorphine products as well as improve their understanding of addiction and 
psychosocial treatments. 
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CHAPTER 1 
1 Introduction 
1.1 Background and Need for Study 
Pain is classified as acute or chronic with chronic pain defined as pain beyond the time of 
normal tissue healing, or three months.26,27 An estimated 43% of adults experience pain of any 
kind in the past 12 months, and the majority of them are working age with an adjusted mean age 
of 44 years.6 Chronic pain can be especially burdensome for the working age population due to 
lost productivity and negative impacts on quality of life.2-6 The most common source of chronic 
pain for those without cancer, referred to as chronic noncancer pain (CNCP), is musculoskeletal 
in origin (joint or back pain), but other sources (e.g. migraine or neuropathic) are also 
prevelant.6,28 
CNCP can be managed using many different therapy regimens including pharmacologic 
options (non-opioid pharmacotherapy and opioid therapy) and non-pharmacologic options which 
have been shown effective (e.g. electrical stimulation, physical therapy, psychological 
interventions, or exercise).7,9,29 CNCP is treated with opioids despite lack of robust evidence on 
the efficacy and effectiveness of COT. Opioids have been recommended to only be used after 
considering a non-opioid analgesic regimen.7 However, in 2012, prescriptions for opioid 
analgesics in the United States peaked at 259 million30 and nearly one in five patients who 
presented to their healthcare provider with a painful condition in 2010 were prescribed an 
opioid.31 Although opioids can treat pain effectively in the short term, the long term effectiveness 
is not established,7,8 yet 35% of adults received opioids for CNCP.10 
Many adults with CNCP who were initiated on opioids transition into COT with adverse 
health consequences; however, research on transitions into long-term opioid use among working 
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age adults is lacking. Although the benefits of long-term opioid therapy (over 1 year) have not 
been sufficiently established in terms of pain, physical functioning, or health-related quality of 
life, 7 the percentage of adults who transition to COT varies widely- from as low as 5% to as high 
as 46%.10,18 While there is substantial published literature on COT among elderly (age > 65 
years),32-34 factors affecting how working-age adults with CNCP transition into COT are less 
well understood.7,35 
Chronic opioid therapy can have serious health consequences.  For example, compared to 
other non-opioid regimens, opioid regimens have been shown to have higher risk for an opioid 
abuse or dependence diagnosis, increased cardiovascular events, endocrinologic harms (e.g. 
androgen deficiency), factures, and acute trauma including vehicle crashes.7,29Other opioid-
related side effects (e.g. xerostomia, nausea, constipation, pruritus, dizziness, vomiting, 
drowsiness) can negatively affect patient’s quality of life.7,36-40 Many opioid users progress to be 
diagnosed with an opioid use disorder which further increases their risk for overdose and 
death.7,10 In a claims-based analysis of those with CNCP, it was reported that long-term opioid 
users were more likely to be diagnosed with opioid use disorder compared to those not 
prescribed opioids.10 Furthermore, COT can exacerbate current conditions and lead to 
development of new chronic physical and mental health conditions.7,19-22  As identified in 
multiple large patient populations, patients with COT (mean ages ranged from 44.6 (SD=15.1) to 
55.4 (13.0) years)  were more likely to develop depression compared to those without opioids 
(HR=1.35, 95%CI=1.26-1.44 in the Veterans cohort to 2.05 (1.75-2.40) in an cohort of enrollees 
in an HMO network). 41 
Preventing inappropriate initiation and utilization of opioid medications is the shared 
responsibility of patients, prescribers, policy-makers, and healthcare payers.7,42 The first step 
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towards preventing opioid misuse and/or addiction is appropriate initiation of opioids because 
persistence in patients with COT is so high.18 In a prospective study, 46% of adults who were 
initiated on opioids transistioned into chronic opioid users.18 One way to aid early identification 
of individuals at high risk for transitioning to COT is through predictive modeling which can be 
used to augment clinicians’ knowledge.43,44 Predictive modeling allows for the inclusion of vast 
amounts of data coming from previously treated patients and can also be applied to real-time 
data customized to specific regions, providers, or insurers.43,44 Early identification of patients 
with certain modifiable risk factors (e.g. opioid dose, opioid duration of action, polypharmacy, 
and number of concomitant pain medications) can help inform early risk mitigation efforts which 
have shown some efficacy at preventing opioid-related adverse events including overdose and 
death.7,45,46 Current CDC opioid prescribing guidelines recommend follow-up earlier than three 
months (before the transition to COT) to increase the likelihood of preventing opioid-related 
adverse events.7 This recommendation was made in light of findings that transitioning to COT 
dramatically increases the risk for opioid use disorders, but there is not enough evidence to 
recommend monitoring intervals or how monitoring should be performed.7,10 
Transition into COT can lead to significant economic consequences, however, robust 
evidence on the effect of transitions to COT on economic consequences is not available. Every 
year, an estimated $78 billion is spent on adverse consequences of opioids including potential 
misuse, abuse, and adverse effects.24 Adverse health effects due to prescription opioids often 
result in increased healthcare utilization and expenditures of working Americans.2-5 For example, 
prescription opioids accounted for over 14,000 overdose deaths, in 2014.47 This can lead to high 
economic burden through increased emergency room, inpatient, and other healthcare utilization 
and healthcare expenditures.19-24 Drug overdoses due to opioids accounted for nearly 7,000 ED 
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visits daily22 and the number of emergency department visits due to opioids have doubled from 
2004 to 2011.19 Over the past two decades, the number of hospital discharges associated with 
opioid overdoses increased by over two and a half times.21 At the patient-level, patients who 
were prescribed opioids had higher emergency department, inpatient, and outpatient visits, as 
well as increased analgesic use, out-of-pocket spending, and third-party spending compared to 
patients not prescribed opioid medications.19,23,48,49   
However, studies that systematically determined the effect of the transition from acute to 
COT has on healthcare utilization and expenditures are lacking.10,20 One study using data from a 
large managed care organization reported that healthcare utilization and expenditures were 
higher among long-term opioid users compare to other opioid users.20This study has many 
serious limitations such as use of non-standard definition of long-term opioid therapy and opioid 
regimen characteristics. The definitions for chronic users (>182 days) were different than the 
Agency for Healthcare Research and Quality (AHRQ) and CDC definition of >90 days (3 
months)7,8, as well as opioid regimen characteristics being categorized as strong or weak.20 
Categorizing opioid regimens based on being “strong” or “weak” does not incorporate potency, 
and if opioids are prescribed in equipotent doses, they are more or less, equally effective.7,26 The 
proposed study will address the serious limitations of the prior literature and analyze the impact 
of transitions from initiation of opioids to COT on the economic burden in a nationally-
representative sample of working age adults using definitions concordant with definitions used 
by CDC, AHRQ, and current literature.7,8,50,51 
While reducing the likelihood of prescribing poorly monitored or inappropriate COT is a 
necessary long-term goal, in the short-term we still need community-based harm reduction 
strategies to prevent unintentional injuries and deaths.46,52-54  Unintentional opioid overdose 
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deaths can be limited by co-prescribing naloxone to patients with high risk COT.7,15 In addition 
to prescribers, current policy and intervention efforts have focused on preventing overdose and 
death (i.e. harm reduction).11-17 Naloxone has been approved in many forms (e.g. intranasal, 
intravenous) and can completely reverse the immediate risks of opioid overdose and prevent 
deaths due to opioid overdose.55,56 State policies are changing to increase accessibility to patients 
as well as their friends, family members, and caregivers. In states where naloxone is already 
available in community pharmacies, pharmacists are helping to prevent opioid-related overdose 
deaths by dispensing naloxone.57 Even with these policy changes, providing naloxone within the 
community is a voluntary act, and needs buy-in from community pharmacists to be effectively 
implemented. 
Pharmacists working in community pharmacies are the most widely available healthcare 
professionals58 and the gatekeepers to prescription opioids as well as the medications used to 
treat opioid use disorder. As dispensers, they typically function in their gatekeeper position while 
possessing little clinical or diagnostic information on the intended indication for opioid use.59 
Despite having little information, pharmacists remain legally accountable to only dispense 
controlled substances for legitimate medical purposes and to reduce diversion.60 Even if the 
information on potentially inappropriate prescribing is available to the pharmacists (e.g. from a 
perception drug monitoring program) the interventions a pharmacist can make are limited.54 This 
obligation has other implications as pharmacists may feel the need to stock less and scrutinize 
more, especially when they feel uncertain about the legitimacy of a controlled substance 
prescription.61 To help alleviate these feelings, provider education must be made available to 
help pharmacists do their jobs more effectively.62 Under ideal circumstances, their provision of 
naloxone is performed as one component of a larger public health mission that includes health 
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promotion, injury prevention, and harm reduction.52 Community pharmacies throughout the 
country have taken on naloxone distribution as part of the public health mission to prevent 
deaths.52 Pharmacists are providing naloxone to the community in unique ways and their legal 
responsibilities are in a state of change.16,17,52,63,64  
West Virginia (WV) is an appropriate state to evaluate the capacity of community 
pharmacies to provide naloxone due to its reliance on community pharmacies to provide access 
to healthcare and its current high levels of opioid abuse and deaths.47,65 In 2015, WV led the US 
with 35.5 deaths per 100,000 inhabitants – twice the national average.47 Lynne Fruth, owner of 
20 community pharmacies in WV supported providing naloxone by stating, “If you live to fight 
another day, you have another chance at recovery.”66 States which have been most burdened by 
the opioid epidemic have used community pharmacists to increase access to naloxone.17,67,68 For 
example, Kentucky (24.7 drug overdose deaths per 100,000 inhabitants) passed legislation for 
pharmacists to provide naloxone in the community in 2015 and the state agencies provide 
education materials tailored to pharmacists in their state.64 Despite the anecdotal successes,46,53 
the true societal impact of naloxone in a community will be determined in the coming months 
and years.  
To optimize the process of providing naloxone to the community in WV requires the 
educational needs of pharmacists to be evaluated as well as their individual perceptions of 
perceived opioid efficacy, perceived naloxone efficacy, and willingness to stock naloxone.  From 
this specific harm reduction strategy to improving initiation of COT, elucidating the transitions 
in opioid use is critical to understanding the opioid epidemic more fully. The findings from this 
study will provide valuable information to clinicians, insurers, policy makers, and researchers 
about these transitions and indicate better options for clinical practice and public health policy. 
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1.2 Specific Aims 
The specific aims are guided by the adapted Continuum of Care for Opioid Misuse 
developed by the Opioid Taskforce for the Alcohol and Drug Abuse Institute at the University of 
Washington.42 The aims of this study are to evaluate the transitions of care a patient may 
experience in their treatment with COT which are all conceptually linked using this framework 
(Figure 1.1).  
AIM 1: Identify leading predictors of transitioning from acute to COT among working age adults 
without cancer with advanced predictive modeling techniques using a nationally representative 
sample of working-age adults. 
Hypothesis 1: Modifiable factors related to opioid regimen such as dose and duration of 
action, polypharmacy, and concomitant pain medications, will be the leading predictors 
of COT in working age adults. 
AIM 2: Analyze the effect of transitions from incident acute opioid therapy to incident COT on 
the trajectories of healthcare utilization and expenditures using a nationally representative 
sample of working-age adults. 
Hypothesis 2: The growth in utilization and expenditures over time will be higher among 
adults who transitioned to COT as compared to adults who did not transition into COT, 
even after adjusting for initial opioid regimen characteristics, comorbidities, and 
demographic information. 
AIM 3: Evaluate the potential for harm reduction capacity, in terms of naloxone distribution 
from community pharmacies, of a high abuse state with assessment of perceptions, behaviors, 
and educational needs of pharmacists licensed and working in West Virginia. 
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1.3 Innovation 
Identification of leading, modifiable predictors using routinely collected data such as 
insurance claims and electronic heath records to identify patients at high risk for with incident 
COT will allow clinicians, policy makers, insurers and other stakeholders develop strategies to 
intervene early for patients. WV is the only state situated entirely within Appalachia, and home 
to people who rank among the oldest, poorest, and least-educated in the US, who face limited 
health care access due to geographic isolation, and have among the highest prevalence of most 
health-related risk factors in the nation. With the recent passage of a WV law allowing 
pharmacists the opportunity to act as naloxone providers, effective educational strategies are 
needed quickly.69 This study can make a significant difference towards solving the opioid-
epidemic in the state. Education has been identified as a key component in reducing opioid abuse 
in the United States.7,62,70 The Extended Parallel Process Model (EPPM) will be used to assess 
educational needs and provide a framework for categorizing types of pharmacists based on their 
perceptions relating to opioid use, misuse, and abuse. EPPM is used for the first time to develop 
public communications for pharmacists. WV is well-known for its limited healthcare 
infrastructure and pharmacists are well-positioned to respond to the opioid crisis.  Evaluating the 
perceptions and actions of the community pharmacists being tasked with providing naloxone in 
their pharmacies has been identified as an important next step by clinicians and promulgated by 
the American Pharmacists Association.63  
1.4 Impact 
By predicting incident COT, clinicians and insurers can personalize treatment options 
including non-opioid regimens for adults at high risk for COT. By tracking the economic burden 
of opioid use from initiation to COT, payers can identify crucial time-windows for designing and 
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implementing value-based designs with financial incentives and disincentives to prevent 
expensive COT and its complications. Further, by evaluating community pharmacists’ readiness 
to support harm-reduction efforts will help regulators, policy makers, and patients in 
implementation of policy around co-prescription of naloxone in community-pharmacies. 
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Figure 1.1 Adapted continuum of care for opioid misuse42 
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CHAPTER 2 
2 Predictors of transitioning to incident chronic opioid therapy among working-aged 
adults 
2.1 Abstract 
Background: Opioids are being prescribed and used for chronic non-cancer pain at prolific rates 
in the United States over the last two decades. Patients who transition to incident chronic opioid 
therapy (COT) are at higher risk for significant, negative health consequences including 
cardiovascular risk, endocrine disorders, opioid use disorder, and death. Objective: The objective 
of this study was to identify leading predictors associated with incident COT among adults 
without cancer in the US. Design: Retrospective observational cohort with claims from a 
nationally-representative sample of adults enrolled in commercial insurance plans. Standard 
parametric (logistic regressions) and non-parametric methods based on decision tree were used 
for prediction. For easier comparison with published literature, we also present adjusted odds 
ratios (AOR) and 95% confidence intervals (CI). Participants:  A 10% random sample of 
working-age adults (age 28-63 years) insured in commercial plans, without cancer and who were 
initiated on opioids between January 2007 through May 2015. Main Measures: Transition to 
incident COT (at least 90 days of opioids claimed within 120 days) after initiation of opioids.  
Predictive models included a comprehensive list of factors available in claims data: opioid 
regimen characteristics, pain conditions, physical and mental health conditions, concomitant 
medications (benzodiazepine, stimulants, non-opioid analgesics, and polypharmacy), patient 
characteristics, and insurance type. Key Results: In our sample, transition to incident COT was 
1.3% and pain-specific diagnoses were rare (31.7%). The four leading predictors of COT were 
opioid duration-of-action [AOR= 12.28; 95%CI= 8.06-18.72], parent opioid [tramadol vs. 
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codeine, [AOR= 7.26; 95%CI= 5.20-10.13], the presence of conditions highly likely to cause 
chronic pain [AOR= 5.47; 95%CI= 3.89-7.68] and drug use disorders [AOR= 4.02; 95%CI= 
2.53-6.40]. Conclusions: Initial opioid regimen characteristics are powerful predictors of COT. 
Predictive algorithms developed from readily available claims data can be used to develop real-
time predictions on future risk of transition to COT. 
2.2 Introduction 
 
Chronic non-cancer pain (CNCP) is prevalent among US adults, has costs exceeding half 
a billion dollars annually, and can be especially burdensome for working-age adults due to lost 
productivity and negative impacts on quality of life.1-6 Many patients suffering from CNCP still 
receive opioid therapy, despite lack of robust evidence on the efficacy and effectiveness of 
opioids relieving CNCP,7,8 and currently-available effective non-opioid treatments.9 In 2012, 
prescriptions for opioids peaked at 259 million prescriptions.7,30  
Patients who receive short-term opioid therapy may be at high risk of becoming users of 
chronic opioid therapy (COT), defined as use of opioid over 90 days.7,18  COT places patients at 
risk of exacerbating current conditions, developing new chronic physical and mental health 
conditions, and opioid-related adverse effects such as overdose, abuse, and death.7,19-22 An 
estimated 1 in 550 patients with CNCP die from an opioid overdose and the rate of death 
increases to 1 in 32 patients, who were prescribed very high daily doses.71  These findings 
suggest that opioid regimen characteristics play a crucial role in escalating the risk of COT and 
its associated adverse consequences.  
However, factors affecting how working-age adults with CNCP transition into COT are 
not well understood.7,35 It is important to examine COT among working-age adults because they 
may suffer from unique, negative consequences such as missed worked days, loss of 
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employment, and decreased productivity19-24  in addition to the complications related to opioids 
such as high economic burden through increased emergency room, inpatient, and other 
healthcare utilization.19-24 Given these potentially serious consequences, it is important to 
determine the predictors of transitioning from acute to COT among working age adults.25 
Identifying working-aged adults who are at high risk for transitioning to COT and determining 
the factors which place them at risk for the transition can augment clinicians’ knowledge to aid 
with prescribing decisions, initial opioid regimen selection, or monitoring,43,44 as well as to help 
inform early risk mitigation efforts, which have shown some efficacy at preventing overdose and 
death.7,45,46   
Researchers have assessed the transition from acute to COT among Veterans, among 
patients using a single healthcare system, or among low-income individuals using Medicaid 
claims.18,72,73  Other studies have used predictive models to identify patients who were diagnosed 
with incident substance use disorders or opioid abuse. 74,75 To date, no study has analyzed the 
transition to incident COT in working-aged adults using nation-wide data.  Therefore, the 
objective of this study was to identify predictors of transition to incident COT among working-
age adults using data from a nationally representative sample of commercially-insured adults in 
the US. With this information, clinicians and insurers can personalize treatment options 
including non-opioid regimens for adults at high risk for transition to COT; changes to treatment 
guidelines based on these predictors can be assessed by researchers, policy makers, and 
government payers. We used robust predictive modeling techniques to identify leading predictors 
of incident COT using readily available information in claims databases; such modeling can be 
applied to real-time data customized to specific regions, providers, or insurers.27,28  
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2.3 Methods 
Data 
 The data were derived from adjudicated claims (inpatient, outpatient, emergency room, 
and prescription) database of commercial enrollees (approximately 150 million enrollees) which 
covered ten years from 2006 to 2015.  The researchers received data on 10% random sample of 
commercial enrollees released under licensing from the QuintilesIMS information services 
(QuintilesIMS RWD Adjudicated Claims - US). The full data from which the 10% was sampled 
covers 90% of hospitals, 80% of doctors, and 85% of large companies in the US. This data only 
includes health plans who submit data for all of their members and the data are considered 
nationally representative for the US commercial-insured population.76,77 
Study Design 
 A retrospective cohort design, with baseline and follow-up periods was used. A patient’s 
first prescription for an opioid during the period between January 2007 and May 2015 was 
defined as the index date; this index date was used to create baseline (12 months before index 
date) and follow-up (120 days after index date) periods. To ensure that we captured individuals 
who were opioid-free in the baseline, we used the first prescription date between January 2007 
and May 2015. The National Drug Codes (NDCs) for opioids were extracted from the National 
Library of Medicine’s (NLM) RxNav (https://mor.nlm.nih.gov/RxNav/) and RxMix 
(https://mor.nlm.nih.gov/RxMix/).78 These conversions allowed for categorizing opioids more 
granularly (e.g. by parent opioid and duration of action). 
Study Sample 
 The study sample (N = 491,422) consisted of adults, aged 28-63 years at index date, 
without cancer, and who were continuously enrolled in a primary, commercial insurance plan 
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during the entire observation period (baseline and follow-up periods). Continuous enrollment in 
both pharmacy benefits and medical benefits was required. We excluded individuals who had 
more than one opioid prescription on the index date because we were unable to evaluate initial 
opioid regimen characteristics for these individuals (N=10,594).  We excluded few individuals 
(N = 23) because of missing of data on region (Figure 2.1). 
Measures 
Dependent variable 
Transition to incident chronic opioid therapy (COT): An enrollee was classified as 
having incident COT if he/she had at least 90-day supply of opioids during the follow-up period 
(i.e. 120 days after index date).  
Independent variables 
Opioid regimen characteristics included duration of action (long-acting and immediate 
release), standardized dose, and parent opioid. These were assessed using the first opioid 
prescription. Parent opioid was grouped into five categories: 1) codeine; 2) hydrocodone; 3) 
oxycodone; 4) tramadol; and 5) other opioids.  As the data use agreement with QuintilesIMS 
specified that opioids manufactured by a single manufacturer could not be isolated, we combined 
all the single manufacturer drugs and other opioids into one category. Methadone can be used to 
treat opioid use disorder or pain, so it was not included as an eligible opioid for the sample. 
Standardized dose was calculated in milligrams of morphine equivalents (mgME) using the 
opioid morphine equivalent conversion factors approved by the Centers for Medicare and 
Medicaid Services (CMS).79 
Enrollment characteristics of patients were: insurance plan type (Health Maintenance 
Organization, Preferred Provider Organization, or other) and primary insured relationship (self, 
 
 
16 
 
spouse, other, and unknown).  Patient demographics included age, sex, and region (East, 
Midwest, South, and West). 
Clinical factors were presence or absence of diagnoses for: painful conditions, mental 
illnesses,80 and a set of  chronic conditions adapted from Department of Health and Human 
Services (DHHS) priority conditions for research, program, and policy.81 Painful conditions were 
also categorized as: 1) conditions highly likely for chronic pain;82 2) likely for chronic pain;82 
and 3) acute pain.83 Arthritis was separated because it was a painful condition as well as a DHHS 
priority condition, so that it would not be double counted. The International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to assess each of 
these conditions.  The ICD-9-CM codes did not overlap between lists. Drug use disorders 
included ICD-9-CM codes for drug dependence (304), drug abuse (305.2-305.9), and drug-
induced mental disorders (292). 
Generic Product Identifier (GPI) codes, a hierarchical classification system that identifies 
drugs from their primary therapeutic use to package size in 2-digit increments, were used to 
assess medication-related characteristics. Medication-related characteristics included 
concomitant use of benzodiazepines (GPI-4 = 57.10), stimulants (GPI-4 = 61.10 or 61.40), or 
non-opioid analgesics (GPI-2 = 66 or 64).  Pharmacotherapy burden was estimated with 
polypharmacy defined as five or more medication classes.84 Concomitant medications were 
measured during the last four months of the baseline period.  
Statistical Analyses: Predictive Modeling  
Both standard parametric (logistic regressions) and non-parametric methods based on 
decision tree were used for prediction. Random forest, a decision tree method is often used for 
predictive accuracy.43  In Random forest, collection of decision trees are built and averaged by 
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bootstrapping of samples and variables.43 The two methods were compared using receiver 
Operator Characteristic (ROC) curves.  Predictive modeling differs from the standard regression 
approaches in many ways. While standard regressions focus on the average relationship between 
transition to COT and explanatory variables, predictive modeling can be used to target the 
patients at highest risk for transitioning to COT like has been done to help develop interventions 
for patients with diabetes.85   
Standard regressions are typically conducted in a given sample, while predictive models 
use bootstrap samples of observations (bagging) and a sample of variables (attribute bagging) 
and testing the estimated model in a hold-out or test sample.43,86  To accomplish this, we 
randomly split the eligible sample into three subsamples (60% training, 20% validation, and 20% 
testing).  After a final model was identified using the training and validation subsamples, the 
predictive model was tested on the hold-out sample to assess performance and potential over-
fitting. To increase the utility of a predictive model in a clinical setting, we used an abbreviated 
set of factors that could be easily assessed during a patient visit (Model 1). Predictive modeling 
was performed in R (R Development Core Team, Vienna, Austria).  For comparison with 
published literature, we present adjusted odds ratios (AOR) and 95% Confidence intervals (CI) 
by conducting a logistic regression of the final models in the test subsample. 
2.4 Results 
Sample description 
 Overall, in this sample of working-aged adults, the transition from first opioid 
prescription to incident COT was 1.3% (n=6,556) (Table 2.1). Hydrocodone was the most 
frequently prescribed first opioid (61.0%) followed by oxycodone (19.3%), tramadol (9.9%), and 
codeine (9.1%). The majority of the eligible sample was female (52.5%), 45 years of age or older 
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(56.7%), and on PPO plans (73.9%). The majority of these patients (68.3%) did not have an 
indication in their medical claims for acute pain, arthritis, or conditions highly likely or likely for 
chronic pain.  
Selected key sample characteristics by transition to COT are presented in Table 2.1. 
Opioid regimen characteristics (parent opioid, duration of action, and standardized dose) were all 
associated with the transition from first opioid prescription to incident COT.  A higher 
percentage of patients with first opioid prescriptions for long-acting formulations (37.0% vs. 
1.3% immediate release), tramadol (4.2% vs 0.5% codeine), very high standardized doses (5.1% 
vs 1.5% lower), patients who had conditions most likely to cause chronic pain (17.2% vs. 1.3% 
without), and patients with drug use disorders (12.4% vs. 1.3% without) transitioned to COT.  
Predictive modeling 
In training/validation subsamples, the following variables were the leading predictors 
after adjusting for sex, age, presence of painful conditions, and readily available and modifiable 
opioid regimen factors (opioid duration of action, parent opioid, and standardized dose).  
Variables of importance (absolute value of the beta-coefficient) in descending order as they 
related to transition to incident COT included: duration of action, likely chronic pain condition, 
parent opioid, highly likely pain condition, and drug use disorder diagnoses.  In the hold-out 
sample, the same predictors were found to be important although the order changed somewhat.  
For example, drug use disorders became the fourth leading predictor in the hold-out sample as 
opposed to second leading predictor in the training/validation samples. In the fully adjusted 
model, the leading predictors remained the same in both training/validation and test samples.  
Again, the order of importance varied somewhat with the drug use disorders variable becoming 
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the fifth leading predicator in the hold-out sample as opposed to third leading predictor in the 
training/validation samples.   
The similarity between the two models was also confirmed by the prediction accuracy of 
Model 1 and fully-adjusted model (Figure 2.2). The Areas under the Curve (AUC) were similar 
for Model 1 (AUC = 0.78) and the fully-adjusted model (AUC = 0.78) using the hold-out 
sample. The AUC of decision-tree based models using random forest on the variables from 
Model 1 and the fully-adjusted model were 0.54 and 0.64 in training/validation subsample, 
respectively.  
As mentioned earlier, for ease of comparisons with published literature, Table 2.2 
summarizes the findings in the form of AOR and 95% CIs from a logistic regression of the test 
sample.  As can be seen from the table, fully-adjusting the model did not make large changes to 
the AORs. For example duration of action (long acting vs. immediate release, AOR = 12.43, 
95% CI = 8.13-18.83) in model 1 was similar in the fully-adjusted model (AOR = 12.28, 95% CI 
= 8.06-18.72). 
2.5 Discussion 
This is the first study to identify incident COT in a sample of working-aged adults, who 
were initiated on opioid therapy. This is an important group to focus on because of the impact on 
productivity and their increased likelihood to receive opioid therapy when they experience 
pain.25 In absolute terms, nearly half a million working-age adults in this sample were initiated 
on opioid therapy over the observation period. For example, in 2014 there were 1,799,106 
million prescriptions for opioid drugs in our 10% sample. As a rate, we found that 13 out of 1000 
patients with initial prescription of opioids transitioned to COT.   
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Another important finding was differences between states in the US. The rates of patients 
who transitioned to incident COT was higher in Ohio, West Virginia, Kentucky, Mississippi, and 
Nevada than other states. These states are often in the media reporting opioid overdoses and 
problems; however, more study could be done to look for specific state issues, including 
monitoring of prescribers, education of public and prescribers, and availability of non-
pharmacotherapy treatments for CNCP. 
Our study findings demonstrated that a smaller set of more easily assessed factors at 
initiation (duration of action, standardized dose, parent opioid, age, sex) can be used to gauge the 
risk of transition to COT.  Our predictive models identified four leading predictors that increased 
the risk of transition to COT by at least four times.  These were: duration of action, type of 
parent opioids, drug use disorders, and painful conditions.  
In our sample of working age adults, the highest likelihood of transition to COT was 
among adults who were prescribed extended release opioids as opposed to immediate release. 
These findings have implications for clinical practice. First, prescribers can use these factors to 
determine the potential for an individual patient to transition to incident COT at the time of their 
first prescription for opioids. With the knowledge of this potential risk, regimens could then be 
altered or monitoring increased.  Pharmacists can also use these factors and provide counseling 
about goals of pain management or the risks of COT, to a subset of patients who are at high risk 
of transitioning to COT. Future intervention efforts can effectively target these factors to change 
prescribing practices of opioids.7  For example, immediate release, low-dose codeine can be first-
line option.  However, other opioids may be needed, since codeine is a weak opioid and there are 
pharmacogenomic differences (e.g. poor metabolizers will have a reduced response) that need to 
be considered for codeine use.87 In addition, future studies using qualitative and quantitative 
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analyses could assess prescriber logic in how they chose to prescribe extended release versus 
immediate release.  What clinical characteristics or patient preference issues were considered in 
making these choices?  There may be underlying issues that are uncovered.    
In our sample, only a third of working-age adults, with first prescription of opioids had 
any diagnosis of painful conditions. While it is plausible that ICD-9-CM codes may under-report 
painful conditions, without the full documentation of indications for opioid use, it is difficult to 
assess appropriateness of initial opioid prescription. This has implications for prescription 
monitoring programs, state-based insurers, health care systems, local hospitals, and outpatient 
practices, as well as emphasizing the need for documentation requirements or recommendations.   
Strengths of this study include the availability of a nationally-representative sample of the 
US commercially-insured population, following individuals across multiple providers and 
settings, use of statistical and machine learning predictive methods, and availability of dates so 
that we could identify first, index opioid prescription. Also, this study assessed incident COT, 
which other studies have not distinguished from prevalent use of chronic or long-term opioid 
therapy. By using the NLM programs RxMix and RxNav to identify clinical drug components, 
the duration of action and parent opioid for each prescription could be identified, which allowed 
for more granular assessment of the opioid regimen using claims data. Finally, the data spanned 
many unique insurers and plan types, which allowed for the tracking of patients through time and 
to determine an opioid-free period of 12 months. 
The study also has some potential limitations. First, prescription claims do not have 
information on variables such as pain, socio-economic status, social capital, medication beliefs, 
and response to pain treatment, which may affect transition to COT. Also, claims data allow for 
the identification of prescription medication, but not actual use of these medications. There are 
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limitations of the predictive modeling results as well. The models were assessed in a unique 
subsample (testing data) of the overall sample. However, the validity of the model and its 
predicted probabilities will be more generalizable if applied to a different sample of patients, 
potentially from other commercial healthcare plans. The importance of factors could change, and 
even be improved if other types of information were added to the dataset (e.g. social 
determinants of health, medication use behaviors, prescriber characteristics).  
2.6 Conclusion 
Our study findings suggest that an individual’s transition to COT can be predicted by 
information readily available in a clinical setting such as the initial opioid regimen 
characteristics, past history of drug use disorder, and painful conditions.  Our study highlighted 
that predictive models can be used to aid clinician’s decision making; develop real-time 
predictions about future risk of transition to COT; influence policy, prescriber education, and 
prescription monitoring programs; and can applied to other patient populations. Future research 
may include other factors, including medication taking behaviors, not measured in our study and 
improve prediction accuracy. 
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Table 2.1. Sample description for patients with incident opioid use by transition to chronic opioid therapy (COT) 
after initial opioid prescription, using QuintilesIMS Real-World Data Adjudicated Claims - US, 2006-2015   
Total (n) Transition to 
COT (n) 
Transition to 
COT (%) 
Χ2 p-value 
All  491,442 6,556 1.3 - - 
Opioid Regimen Characteristics 
Duration of action of initial opioid prescription 
 
7926.7 <0.001 
 
Long acting 819 303 37.0  
 
 
Immediate release 490,623 6,253 1.3  
 
Parent opioid of initial opioid prescription 
 
 4494.2 <0.001 
 
Codeine 44,588 201 0.5  
 
 
Hydrocodone 300,008 3,023 1.0  
 
 
Oxycodone 94,822 1,039 1.1  
 
 
Tramadol 48,450 2,039 4.2  
 
 
All other opioids 3,574 254 7.1  
 
Standardized dose* of initial opioid prescription 674.4 <0.001 
 
Lower (0-49) 370,726 5,520 1.5  
 
 
Moderate (50-99) 106,544 776 0.7  
 
 
High (100-149) 11,399 118 1.0  
 
 
Very high (≥150) 2,773 142 5.1  
 
Pain Conditions 
Highly likely chronic pain condition 
  
2883.8 <0.001 
 
Yes 1,508 259 17.2  
 
 
No 489,934 6,297 1.3  
 
Likely chronic pain condition 
  
 2029.9 <0.001 
 
Yes 144,644 3,581 2.5  
 
 
No 346,798 2,975 0.9  
 
Acute pain condition 
  
 26.5 <0.001 
 
Yes 4,247 95 2.2  
 
 
No 487,195 6,461 1.3  
 
Arthritis     1241.5 <0.001 
 Yes 30,811 1,098 3.6   
 No 460,631 5,458 1.2   
Physical and Mental Health Conditions 
Mental illness 
  
 462.5 <0.001 
 
Yes 58,356 1,338 2.3  
 
 
No 433,086 5,218 1.2  
 
Any drug use disorder 
  
 1401.7 <0.001 
 
Yes 1,513 187 12.4  
 
 
No 489,929 6,369 1.3  
 
Concomitant Medications 
Benzodiazepine use within four months preceding opioid prescription 612.0 <0.001 
 
Yes 39,048 1,059 2.7  
 
 
No 452,394 5,497 1.2  
 
Continued       
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Table 2.1. Sample description for patients with incident opioid use by transition to chronic opioid therapy (COT) 
after initial opioid prescription, using QuintilesIMS Real-World Data Adjudicated Claims - US, 2006-2015   
Total (n) Transition to 
COT (n) 
Transition to 
COT (%) 
Χ2 p-value 
Stimulant use within four months preceding opioid prescription 105.2 <0.001 
 
Yes 7,642 204 2.7  
 
 
No 483,800 6,352 1.3  
 
Non-opioid analgesic use within four months preceding opioid prescription 117.9 <0.001 
 
Yes 120,486 1,983 1.6  
 
 
No 370,956 4,573 1.2  
 
Polypharmacy (≥5 drug groups) 
 
 528.9 <0.001 
 
Yes 109,724 2,234 2.0  
 
 
No 381,718 4,322 1.1  
 
Patient Characteristics 
Sex 
    
94.0 <0.001 
 
Male 233,393 3,503 1.5  
 
 
Female 258,049 3,053 1.2  
 
Age 
 
   594.2 <0.001 
 
28-34 years 81,462 602 0.7  
 
 
35-44 years 130,917 1,345 1.0  
 
 
45-54 years 156,191 2,332 1.5  
 
 
55-63 years 122,872 2,277 1.9  
 
Region 
 
   67.2 <0.001 
 
East 94,910 1,075 1.1  
 
 
Midwest 156,117 2,090 1.3  
 
 
South 194,746 2,862 1.5  
 
 
West 45,669 529 1.2  
 
Insurance Characteristic 
Insurance plan type 
  
 24.0 <0.001 
 
HMO 63,181 798 1.3  
 
 
PPO 363,414 5,010 1.4  
 
 
Other† 64,847 748 1.2  
 
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified 
between 2007-2015 and had enrollment between 2006-2015. These patients were between 28-63 years old, 
without cancer, had complete demographic information available, and had only one opioid prescription on the 
index date. Due to data use requirements, some categories were collapsed. These include insurance plan type and 
other opioids. 
*: Doses of opioids were converted to a standardized dose (milligrams of morphine equivalent) using the Centers 
for Medicare and Medicaid Services conversion table. 
†: Other insurance types included fee-for-service, health savings account, and indemnity. 
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Table 2.2. Select leading predictors from a logistic regression with adjusted odds ratio (AOR) and 95% confidence 
interval (95%CI) for patients with incident opioid use by transition to chronic opioid therapy (COT) after first opioid 
prescription, using QuintilesIMS Real-World Data Adjudicated Claims - US, 2006-2015   
Model 1 in  
Test subsample 
 
Fully adjusted Model 2 
 in Test Subsample   
AOR 95% CI Sig 
 
AOR 95% CI Sig 
Long-acting vs. Immediate release 
 
12.43 [8.13,18.83] *** 
 
12.28 [8.06,18.72] *** 
Tramadol vs. Codeine 
 
7.59 [5.53,10.74] *** 
 
7.26 [5.20,10.13] *** 
Highly likely chronic pain vs. None 
 
5.91 [4.18,8.20] *** 
 
5.47 [3.89,7.68] *** 
All other opioids vs. Codeine 
 
5.71 [3.38,9.59] *** 
 
5.64 [3.34,9.53] *** 
Drug use disorder diagnosis vs. None 
 
4.96 [3.13,7.58] *** 
 
4.02 [2.53,6.40] *** 
Oxycodone vs. Codeine 
 
2.70 [1.92,3.90] *** 
 
2.67 [1.87,3.81] *** 
Likely chronic pain vs. None 
 
2.08 [1.84,2.34] *** 
 
2.02 [1.79,2.28] *** 
Hydrocodone vs. Codeine 
 
2.04 [1.49,2.87] *** 
 
1.97 [1.42,2.73] *** 
Benzodiazepine prescription vs. None 
 
1.99 [1.69,2.33] *** 
 
1.82 [1.54,2.16] *** 
Arthritis vs. None 
 
1.92 [1.63,2.25] *** 
 
1.86 [1.58,2.20] *** 
Male vs. Female 
 
1.43 [1.27,1.60] *** 
 
1.46 [1.30,1.65] *** 
Very high vs. Low dose† 
 
1.27 [0.73,2.08] 
  
1.24 [0.74,2.08] 
 
Age (continuous) 
 
1.02 [1.02,1.03] *** 
 
1.02 [1.01,1.03] *** 
High vs. Low dose† 
 
0.71 [0.47,1.05] 
  
0.68 [0.45,1.02] 
 
Moderate vs. Low dose† 
 
0.45 [0.37,0.55] *** 
 
0.45 [0.37,0.54] *** 
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified 
between 2007 and 2015 and had enrollment between 2006 and 2015. These patients were between 28-63 years old, 
without cancer, had complete demographic information available, and had only one opioid prescription on the index 
date. Due to data use requirements, some categories were collapsed. These include insurance plan type and other 
opioids. Other variables included in the fully adjusted model can be seen in the supplemental materials.  
†: Doses of opioids were converted to a standardized dose (milligrams of morphine equivalent) using the Centers for 
Medicare and Medicaid Services conversion table. 
Significance: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = * 
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Figure 2.1. Application of inclusion and exclusion criteria to the sample of patients with incident opioid 
prescriptions from QuintilesIMS Real-World Data Adjudicated Claims – US, which were identified between 2007 
and 2015. 
 
  
 
 
28 
 
Figure 2.2: Receiver operator characteristic (ROC) curves for Model 1 (orange, AUC = 0.776) and Fully Adjusted 
Model 2 (purple, AUC = 0.782) using the test subsample 
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CHAPTER 3 
3 Increased healthcare utilization and expenditures associated with transition to chronic 
opioid therapy 
3.1 Abstract 
Objective: To assess the association between transitioning from incident opioid use to chronic 
opioid therapy (COT), on the trajectories of health utilization and expenditures Data sources: 
Commercial claims database (10% sample of QuintilesIMS Real-World Data Adjudicated 
Claims – US) from 2006-2015 Study design: Longitudinal, retrospective cohort design, using 
seven, 120-day time periods covering pre-index (t1- t3), index (t4), and post-index (t5- t7) with 
data from adults, aged 28-63 years, without cancer, and who were continuously-enrolled in a 
primary, commercial insurance plan (n= 20,201). Multivariable analyses were performed on 
utilization [population-average (PA) logistic regression], expenditures (PA generalized 
estimating equations), and expenditure estimates (counterfactual prediction). Data 
collection/extraction methods: Fully-adjudicated pharmacy, hospital, and medical claims sourced 
from commercial payers Principal findings: Patients who transitioned to COT were more likely 
to use inpatient services [AOR=1.11, 95%CI(1.01,1.21)] compared to those who did not 
transition. While expenditures peaked during the transition period (t4) for all users, differences in 
unadjusted average, 120-day expenditures between COT and no COT users were highest in t4 for 
total ($4,607) and inpatient expenditures ($2,453). COT users had significantly higher total 
(=0.183, p<0.01) and inpatient expenditures (=0.448, p<0.001). Conclusions: The period after 
incident opioid prescription, but before COT, is an important time for intervention for payers. 
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3.2 Introduction 
Nearly half of Americans have experienced pain in the past year, and approximately 100 
million suffer from chronic pain 1,3. The vast majority of these patients suffer from pain not 
related to cancer, also known as chronic non-cancer pain (CNCP), and are working age 1,2,4-6. 
CNCP can be managed using many different therapy regimens including pharmacologic options 
(non-opioid pharmacotherapy and opioid therapy) and non-pharmacologic options, which have 
been shown effective (e.g. electrical stimulation, physical therapy, psychological interventions, 
or exercise) 7,9,29. Opioids have been recommended to be used only after considering a non-
opioid analgesic regimen. Nearly one in five patients who presented to their healthcare provider 
with a painful condition in 2010 were prescribed an opioid even though the effectiveness of 
opioids in relieving non-cancer pain has not been proven 31.  
In addition to the lack of evidence for opioids to treat CNCP, they also lead to adverse 
health consequences including cardiovascular risk, endocrine disorders, opioid use disorder, and 
death 7. Multiple studies have also documented increased healthcare utilization and expenditures 
to patients and payers due to adverse health effects of opioids 3-5,23. Patients who were prescribed 
opioids had higher emergency department, inpatient, and outpatient visits, as well as increased 
analgesic use, out-of-pocket spending, and third-party spending compared to patients not 
prescribed opioid medications 19,23,48,49. For example, prescription opioids accounted for nearly 
16,000 age-adjusted overdose deaths, in 2015 88. This can lead to high economic burden through 
increased emergency room, inpatient, and other healthcare utilization and healthcare 
expenditures 19-24. Using older data from 2011, it has been reported that 1,000 people were 
treated in emergency rooms daily for misuse of prescription opioids 22. The number of annual 
emergency department visits due to opioids doubled from 2004 to 2011 19. From 1993 to 2012, 
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the rate of hospital inpatient stays related to opioid overuse, per 100,000 population, increased 
from 116.7 to 295.6, a cumulative increase of 153%.21  
 Patients who receive initial opioid therapy, even for only a few days, are at risk of 
transitioning to chronic opioid therapy (COT), defined as 90 days of use 7,18. For example our 
preliminary analysis has shown that initial opioid prescription characteristics (parent opioid, 
duration of action, and standardized dose) are the leading predictors of transitioning to COT 89. 
Another, prospective, study found that expectations about opioid use in the future predicted COT 
18. Both patients and payers can bare the economic consequences of COT, which results from 
exacerbation of current medical conditions, development of new physical and mental health 
conditions, and opioid-related adverse effects including drug use disorder, and opioid overdose 
7,19-22. Every year, an estimated $78 billion is spent on these adverse consequences of opioids 24.  
Although researchers have estimated the economic burden of developing an opioid use 
disorder in patients on opioid therapy 24,49,90; studies that systematically examined the effect of 
the transition to COT has on healthcare utilization and expenditures are sparse 10,20.  Such studies 
are important because they assess a transition state generally earlier in patient’s continuum of 
care 42, and this earlier period has been identified by the Centers for Disease Control and 
Prevention (CDC) as a time to take action 7. To date, only one study analyzed the association 
between long-term opioid therapy and other opioid therapy on healthcare utilization and 
expenditures 20.  Using data from commercial health plans, the study reported that healthcare 
expenditures were higher among long-term opioid users compared to other opioid users 20. This 
study had some limitations such as use of non-standard definition of long-term opioid therapy, 
and unequal follow-up time periods between short- and long-term opioid users. The definition 
for chronic opioid users (>182 days) was different from the commonly-used Agency for 
 
 
32 
 
Healthcare Research and Quality (AHRQ) and CDC definition of ≥90 days (3 months) 7,8. 
Furthermore, the study was not restricted to working-age adults who may have different 
transition rates and factors affecting those rates. Our study addresses the limitations of the prior 
literature and analyzes the impact of transitions from initiation of opioids to COT on economic 
outcomes in a nationally-representative sample of working age adults using definitions 
concordant with definitions used by CDC, AHRQ, and current literature 7,8,50,51.  
Focusing on working age adults in the age group 18-64 years is important because this 
group may have higher risk of transition to COT transition 91 and their healthcare utilization 
patterns may be unique compared to the elderly 92. Therefore, the objective of our study was to 
assess the association between transitioning from incident opioid use to incident chronic opioid 
therapy (COT), on the trajectories of health utilization and expenditures using a nationally-
representative sample of commercially-insured working-aged adults in the United States (US). 
3.3 Methods 
Data Source 
The data were derived from a 10% random sample of commercial enrollees released 
under licensing from the QuintilesIMS (QuintilesIMS RWD Adjudicated Claims - US). 
Study design 
 A retrospective cohort design with longitudinal data for seven, 120-day, time periods 
covering pre-index (t1, t2, and t3), index (t4), and post-index (t5, t6, and t7) was used. The patient 
cohort consisted of working aged adults, without cancer and who were initiated on opioids 
between January 2007 and May 2014. The first observed prescription for an opioid represented 
the index date. The pre-index periods were identified before the index date, the index period was 
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identified as 120 days after the index opioid prescription, and the post-index periods were 
identified after the end of the index period. 
Study sample 
 The sample was restricted to adults, aged 28-63 years at index date, without cancer, and 
who were continuously enrolled in a primary, commercial insurance plan during the entire 
observation period. The patient age of 63 was chosen so that full index and post-index periods 
would still result in a patient less than 65 years (the age in which they are eligible for Medicare). 
Cancer was identified using the International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes. Patients with at least one claim with any cancer code (except 
for non-melanoma skin cancer) in any of the 12 diagnosis code fields available in the claims data 
were considered as having cancer 81. Continuous enrollment in both pharmacy benefits and 
medical benefits was required. We excluded individuals who had more than one opioid 
prescription on the index date because we were unable to evaluate initial opioid regimen 
characteristics for these individuals. After applying the exclusion criteria, we observed 3,776 
adults in the COT group.  A 5% random sample, approximately 5 controls per case, of patients 
without COT was selected to represent the No COT group (N = 16,425) (See Appendix 1).  
Measures 
Dependent variables: Healthcare utilization and expenditures  
All healthcare utilization and expenditures were repeatedly measured for each time 
period. Utilization consisted of emergency department (ED) and inpatient. ED  use was 
identified using previously published algorithm based on place of service, procedure codes, and 
revenue center codes 93. Inpatient use was identified based on the claim having a non-missing 
value for confinement number (a unique number with the claims, indicating hospitalization). 
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Inpatient claims with the same confinement number were aggregated to get the admission and 
discharge dates. We measured utilization by any use of ED or inpatient, defined as having at 
least one claim for these services during the 120-day time period. 
Expenditures were distinguished by type of service [ED, inpatient, physician, and other 
(e.g. surgical services, diagnostics, and laboratory tests)]. Total expenditures (without 
prescription drugs) were the sum of ED, inpatient, physician, and other. Expenditures were 
calculated using the actual amount paid by the insurance plan; they were converted to 2015 US 
dollars using the US Bureau of Labor Statistics Consumer Price Index (CPI) for Medical Care 
Services 94. 
Key independent variable 
 Transition to incident chronic opioid therapy (COT): Opioids were identified using the 
National Drug Codes (NDCs).  NDCs for opioids were extracted from the National Library of 
Medicine’s (NLM) RxNav (https://mor.nlm.nih.gov/RxNav/) and RxMix 
(https://mor.nlm.nih.gov/RxMix/) 78. A patient was classified as having incident COT in he/she 
had at least 90-day supply of opioids during the 120-day index period.  
Other independent variables 
 Time invariant characteristics (patient’s sex, region of residence, and clinical factors) 
were measured during the 12 months before index date. Age was calculated as of the index date 
for initial opioid prescription. Clinical factors were presence or absence of diagnoses for: painful 
conditions 82, mental illnesses 80, drug use disorders, and number of other chronic conditions 
adapted from Department of Health and Human Services (DHHS) priority conditions for 
research, program, and policy.81 Painful conditions were categorized as conditions highly likely 
for chronic pain or likely for chronic pain 82. Drug use disorders included ICD-9-CM codes for 
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drug dependence (304), drug abuse (305.2-305.9), and drug-induced mental disorders (292). The 
ICD-9-CM codes were used to assess each of these conditions and did not overlap between lists.  
The clinical complexity of a patient was also measured during each time period by the 
number of unique medication classes. We also assessed concomitant medication use, specifically 
benzodiazepines and prescription non-opioid analgesics, at each time period. Generic Product 
Identifier (GPI) codes were used to identify number of unique medication classes, as well as 
benzodiazepines (GPI-4 = 57.10) and prescription non-opioid analgesics (GPI-2 = 66 or 64). 
Additional independent variables included continuous time (range 0-6 corresponding to t1-t7) and 
an indicator variable for the index period (t4) to capture the differential rates of healthcare 
utilization and expenditures during this period. 
Statistical Analyses 
As we repeatedly measured healthcare utilization, expenditures, unique medication 
classes, and concomitant medication use every 120-days, each individual had seven observations. 
These seven observations were not independent and applying standard regression techniques can 
lead to misleading results. Therefore, the unadjusted and adjusted relationships between COT 
and economic outcomes were analyzed with a repeated measures design. Healthcare 
expenditures are unique (e.g. non-normal distribution, high number of enrollees with zero-
values, and non-negative measurement of the outcomes of interest). Therefore, we used the 
generalized linear mixed models (GLMM), which can accommodate both linear and non-linear 
outcome variables. Mixed-effects regressions can model both within and between subject 
variations. However, one needs to distinguish between population-averaged (PA) and subject-
specific (SS) models for binary outcomes 95 as well as continuous outcomes within GLMM. We 
used PA models with generalized estimating equations (GEE) to analyze the relationship 
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between COT and ED use, inpatient use, and expenditures.  For this study, the population 
average (PA) approach was used because the objective was to estimate the average treatment 
effects between the COT and non-COT group.  In multivariable GEE models, we adjusted for 
time as a continuous variable (range 0-6), number of other chronic conditions, sex, age, region, 
history of drug use disorder, painful conditions, benzodiazepine use, non-opioid analgesic use, 
and number of unique medication classes.  
Three models were developed to analyze the relationship between COT indicator and the 
dependent variables. The first model (Model 1) is only adjusted for continuous time, and the 
index period (t4). Model 2 additionally adjusted for the number of chronic conditions, while 
Model 3 is the fully adjusted model and includes additional adjustments for sex, age, region, 
history of drug use disorder, painful conditions, benzodiazepine use, non-opioid analgesic use, 
and number of unique medication classes. 
We calculated the differences in average expenditures between COT and no COT groups 
with a counterfactual prediction technique. This was done because exponentiating expenditures 
for the COT and no COT groups to derive absolute differences in dollar amount assumes a 
reference case scenario. Rather than simply comparing the expenditures between the groups, by 
holding other variables constant, we used the counterfactual prediction technique. Under this 
technique, expenditures for counterfactual scenarios (e.g. assuming all patients with and without 
COT while keeping their other characteristics as given) were calculated and differences in 
average expenditures were estimated 96-99. Confidence intervals for these estimates were obtained 
using 1000 bootstrap replications using the percentile method. Datasets for these analyses were 
created using SAS (version 9.4) and analyses were performed using STATA (version 14). 
Inverse Probability of Treatment Weighting 
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Patients receiving COT or non-COT regimens may systematically differ in observed 
characteristics (e.g. painful conditions). Therefore, to control for observed selection bias between 
patients transitioning to COT and those not transitioning to COT, we used inverse probability of 
treatment weighting (IPTW) 100.  Patient sex, age categories, region, and pain conditions were 
used in a logistic regression on COT use to derive IPTW and were used as patient weights in 
designated analyses. 
3.4 Results 
Description of the study sample by COT 
The sample characteristics (sex, age, region, and pain conditions) were significantly 
different between COT and non-COT groups (all p<0.001). After adjustment for IPTW, there 
were no longer any significant differences. The sample comparison before and after IPTW is 
displayed in Supplemental Table 7.2.1. 
Healthcare utilization 
 ED utilization differed significantly across time periods (p<0.001) between patients that 
transitioned to COT compared to those who did not, in the unadjusted analyses (Table 3.1). For 
patients with COT, ED use increased from 6.0% (t1) to 15.5% (t4); similarly, for patients without 
COT, ED use increased from 4.3% (t1) to 15.3% (t4). ED use remained higher in the COT group 
as compared to the no COT group in the follow up time periods (t5, t6, and t7). As displayed in 
Table 3.2, using adjusted Models 1 and 2, patients who transitioned to COT were more likely to 
have ED utilization [AORs=1.33,95%CI(1.25,1.42) and 1.26(1.17,1.34), respectively] compared 
to those who did not transition to COT. However, in Model 3, the patients who transitioned to 
COT were less likely to have ED use [AOR=0.92, 95%CI(0.86,0.99)].  
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Similarly, inpatient use increased from 1.5% (t1) to 10.9% (t4) in patients with COT; for 
patients without COT, inpatient use increased from 1.1% (t1) to 5.4% (t4) (Table 3.1). Inpatient 
use remained higher in the COT group as compared to the no COT group in the follow-up time 
periods (t5, t6, and t7). Patients who transitioned to COT were more likely to have inpatient use in 
all three models [AOR= 1.78 95%CI(1.63,1.94), 1.45 (1.33,1.58), and 1.11 (1.01,1.21), for 
Models 1, 2, and 3, respectively] (Table 3.2). Finally, both ED and inpatient use were more 
likely to occur during the index period (t4) compared to all other periods (p<0.001) (Table 3.2).  
Healthcare expenditures 
 Average expenditures over time and by COT use are summarized in Table 3.3 and 
differences in unadjusted mean expenditures over time, among COT and non-COT users by type 
of service, are graphed in Supplemental Figure 7.2.1. Patients who transitioned to COT had 
higher total expenditures at every time point, and the difference in mean expenditures between 
these groups varied significantly as time progressed. In t1, the patients that transitioned to COT 
only had $511 higher total expenditures, but that increased to $4,607 in t4. The differences in 
average expenditures peaked during the index period (t4) and remained higher than baseline 
through the entire follow-up period, driven mostly by inpatient expenditures.  
 Patients who transitioned to COT had significantly higher total (p=0.002) and inpatient 
(p<0.001) expenditures in the fully adjusted analyses (Table 3.4). Also, the index period (time 
period 4) was associated with higher expenditures for every type, compared to baseline. In the 
fully adjusted model, we observed a difference of $579 in t4 between COT and non-COT users 
using the counterfactual prediction technique (Figure 3.1). 
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3.5 Discussion 
Generally, healthcare utilization and expenditures were higher during the index period (t4) 
compared to all other time periods for all opioid users (regardless of transition to COT). The only 
exception to this was for non-COT users, inpatient expenditures were higher in t3. For those with 
and without transition to COT, expenditures increased by 594% and 698% in the period prior to 
the initial prescription of opioids (t1 to t3) suggesting that the periods surrounding the initial 
opioid prescription are associated with high utilization and expenditures.   However, COT users 
had higher rate of increase in expenditures as compared to no COT users.  
Most trajectories of healthcare utilization and expenditures (from t1 through t7) were 
different between COT and non-COT users. For example, among COT users, healthcare 
utilization and expenditures were the highest at the index period (t4), but for those who did not 
transition to COT, the peak utilization and expenditures were observed in t3, prior to initial 
opioid receipt. Furthermore, for patients who transitioned to COT, the utilization and 
expenditures remained higher than baseline. For patients who did not transition to COT, 
utilization and expenditures returned to closer to initial pre-opioid levels measured at t1 after 
adjusting for other characteristics. 
 In the fully-adjusted models, transition to COT was associated with higher inpatient 
utilization and inpatient expenditures as well as total expenditures (without prescription drugs). 
The has implications for payers because inpatient use has been reported to be the primary driver 
of total expenditures 20. In our study, the proportion of inpatient expenditures to total 
expenditures varied from 50% (t1) to 80% (t3) in COT users.  
Any intervention focused on curbing transition to COT has the potential to prevent 
inpatient use and can lead to cost savings for the payer(s). Interventions include extensive 
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physician and patient education about pain management and opioids, the further interoperability 
of state-level prescription drug monitoring programs, and increase options for disposal of unused 
opioid medications 101. Future research could use this study as part of the way to assess the cost 
effectiveness of the mentioned interventions. In addition to expenditures, reduction in inpatient 
utilization has benefits for the patient including improved quality of life and lower out of pocket 
costs. 
 Without adjustments for patient complexity (e.g. number of unique medication classes, 
highly likely chronic pain conditions, and likely chronic pain conditions), patients who 
transitioned to COT were more likely to use ED as compared to patients who did not. However, 
in the fully-adjusted model, ED use was less likely between patients who transitioned to COT 
compared to those who did not. While we do not know the reasons for this counter-intuitive 
finding, we speculate that ED use may be due to patient complexity requiring pain management, 
which may have led to an initial prescription of opioid in the index period (t4). Initial prescription 
for opioids may have provided short-term relief decreasing their need for emergency care.  
Although not directly comparable, our study findings were similar to the study published 
by Kern, et.al. assessing the transition from initial opioid prescription to long-term opioid use 20. 
For example, Kern, et.al. reported that for long-term users of opioids, healthcare utilization rates 
(e.g. ED, inpatient, and outpatient visits) and costs decreased after the first 6 months of follow-
up, but remained above the baseline levels 20. Kern et.al. also reported that the number of ED 
visits per patient-year of follow-up were lower for patients receiving long-term opioid therapy 
compared to short-term use (0.44 vs. 0.93).  
Strengths and limitations 
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Strengths of this study include the use of a nationally-representative sample of the US 
commercially-insured population, following individuals across multiple providers and settings. 
This longitudinal design with repeated measures of utilization and expenditures for patients with 
and without transition to COT allowed for an assessment of baseline utilization and expenditures. 
This allowed us to control for baseline profiles in terms of utilization, expenditures, and patient 
complexity. The data spanned many unique insurers and plan types, which allowed for the 
tracking of patients through time and to determine an opioid-free period of 12 months (t1-3). 
Furthermore, we applied robust statistical methods to control for observed selection bias. 
 This study also has some potential limitations. We only observed prescription claims and 
not actual use of medications. The database did not have information on variables such as pain, 
socio-economic status, social capital (i.e. social relationships that have benefits to production), 
medication beliefs, and response to pain treatment, which may have affected the transition and 
associated healthcare utilization and expenditures. Although observed selection bias was 
controlled for, we did not control for selection bias due to unobserved characteristics. Thus, all 
selection bias may not have been eliminated. 
3.6 Conclusion 
Transitioning to COT can place a significant economic burden on payers and patients in 
terms of healthcare utilization and expenditures. Despite having similar baseline values, patients 
making the transition to COT had persistently high levels of utilization and expenditures even 
after 12 months following the transition to COT. The period of time after incident opioid 
prescription, but before COT, is an important time for intervention for payers and clinicians. 
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Table 3.1. Rates of emergency department (ED) and inpatient use by transition to chronic opioid 
therapy (COT) after initial opioid prescription 
QuintilesIMS Real-World Data Adjudicated Claims Database- US, 2006-2015 
 Emergency Department Use* Inpatient Use * 
Time COT (Wt. %) No COT (Wt. %) COT (Wt. %) No COT (Wt. %) 
1 6.0 4.3 1.5 1.1 
2 5.5 4.1 1.7 0.9 
3 11.2 12.4 5.9 9.2 
4 15.5 15.3 10.9 5.4 
5 11.4 5.3 5.9 1.9 
6 10.1 5.7 4.5 2.2 
7 9.3 5.2 4.0 1.6 
 Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were 
identified between 2007-2014 and had enrollment between 2006-2015. These patients were between 
28-63 years old, without cancer, had complete demographic information available, and had only one 
opioid prescription on the index date. Individual weights based on IPTW have been used for this 
analysis. 
*: Significant differences in ED use and IP use by COT category over time using chi-square tests 
Abbreviations: COT- chronic opioid therapy; Wt- weighted 
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Table 3.2 Adjusted odds ratio (AOR) and 95 % confidence intervals (95%CI) of selected Variables 
From population-average Generalized Estimating Equations 
Working-Age Adults with incident Opioid Prescription 
QuintilesIMS Real-World Data Adjudicated Claims Database - US, 2006-2015 
  Emergency Department Use Inpatient Use 
Model 1: Adjusted for COT, Time and Index Period(t4) 
Variables AOR 95% CI Sig AOR 95% CI Sig 
 COT 1.32 [1.25,1.42] *** 1.78 [1.63,1.94] *** 
 Time 1.04 [1.03,1.06] *** 1.04 [1.03,1.06] *** 
 Index Period (Time 4) 2.26 [2.12,2.40] *** 1.62 [1.43,1.83] *** 
Model 2: Adjusted for COT, Time Index Period(t4), and Number of other Chronic Conditions 
 COT 1.25 [1.17,1.34] *** 1.45 [1.33,1.58] *** 
 Time 1.04 [1.03,1.06] *** 1.05 [1.03,1.07] *** 
 Index Period (Time 4) 2.27 [2.13,2.41] *** 1.81 [1.62,2.02] *** 
Model 3: Adjusted for COT, Time Index Period (t4), and Number of other Chronic Conditions, Sex, 
Age, Region, History of Drug Use Disorder, Painful Conditions, Benzodiazepine Use, Non-opioid 
Analgesic Use, and Number of Unique Medication Classes. 
 
 COT 0.92 [0.86,0.99] * 1.11 [1.01,1.21] * 
 Time 0.99 [0.98,1.00]  0.978 [0.96,0.99] * 
 Index Period (Time 4) 1.64 [1.54,1.75] *** 1.13 [1.00,1.29]  
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified 
between 2007-2014 and had enrollment between 2006-2015. These patients were between 28-63 years old, 
without cancer, had complete demographic information available, and had only one opioid prescription on the 
index date. Individual weights based on inverse probability of treatment weighting (IPTW) have been used for 
this analysis. 
Abbreviations: COT- chronic opioid therapy; Wt- weighted; AOR- adjusted odds ratio;  
Sig: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = * 
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Table 3.3 Average expenditures (2015 US dollars) over time by Type of Service and Chronic Opioid Therapy 
(COT) use 
Working-age Adults (aged 28 – 63) without Cancer and initiated on Opioid Therapy 
QuintilesIMS Real-World Data Adjudicated Claims Database- US, 2006-2015 
 COT  
Mean                                        (SD) 
No COT  
Mean                              (SD) 
Time Total Expenditures†*** 
t1 $1,214.29 $5,370.49 $702.98 $3,381.23 
t2 $1,533.36 $10,527.42 $718.73 $3,020.19 
t3 $4,750.20 $22,883.82 $3,394.63 $13,281.89 
t4 $8,086.02 $24,328.52 $3,478.55 $9,558.53 
t5 $4,615.81 $16,668.22 $1,480.62 $7,397.14 
t6 $3,951.71 $16,045.87 $1,574.25 $8,258.62 
t7 $3,382.53 $12,654.83 $1,289.55 $6,838.75 
Time Emergency Department*** 
t1 $54.05 $329.90 $44.82 $586.10 
t2 $73.02 $730.37 $41.16 $417.54 
t3 $173.96 $1,111.67 $147.68 $800.61 
t4 $222.88 $983.72 $176.51 $809.45 
t5 $153.36 $837.10 $69.24 $594.06 
t6 $146.19 $784.20 $70.24 $487.89 
t7 $138.94 $848.86 $66.82 $521.07 
Time Inpatient*** 
t1 $315.00 $3,406.36 $130.71 $2,358.01 
t2 $566.30 $9,071.37 $93.45 $1,654.38 
t3 $2,997.45 $19,703.13 $1,854.68 $11,325.91 
t4 $3,173.69 $14,809.44 $720.86 $5,742.17 
t5 $1,697.03 $11,374.53 $400.90 $4,628.53 
t6 $1,425.95 $11,967.43 $479.34 $5,169.43 
t7 $1,185.19 $7,703.07 $345.73 $4,476.01 
Time Physician*** 
t1 $156.40 $320.98 $121.20 $250.30 
t2 $166.67 $334.31 $131.08 $267.03 
t3 $217.43 $391.12 $185.82 $309.58 
t4 $419.98 $687.52 $221.31 $434.49 
t5 $300.25 $536.57 $150.35 $312.71 
t6 $251.91 $438.32 $145.46 $332.52 
t7 $218.46 $401.72 $125.01 $302.37 
Note:  Based on working age adults without cancer, initiated on opioid therapy between 2007 and 2014, aged 
between and aged between 28 and 63, had only one opioid prescription on the index and had continuous enrollment 
for 29 months in a commercial insurance plan.  The data were from the QuintilesIMS RWD Adjudicated Claims – 
US.  Differences in average expenditures between COT users and No COT users were tested using generalized 
estimating equation models. 
† Total expenditures are sum of emergency department, inpatient, physician and other costs and excludes 
prescription drug expenditures.  Other category is not displayed, thus, the sum of average inpatient, emergency 
department and physician expenditures will not add up to average total expenditures. 
***  p<0.001. 
Abbreviations: Rx- prescription; US: United States; SD = Standard Deviation 
 
  
 
 
46 
 
 
  
Table 3.4 Weighted and adjusted expenditures over time for patients with incident opioid use by 
transition to chronic opioid therapy (COT) after first opioid prescription, 
QuintilesIMS Real-World Data Adjudicated Claims Database - US, 2006-2015 
Cost Type COT Index Period (Time 4)  Intercept 
Total (No RX) β SE p-value β SE p-value β SE p-value 
 Model 1 0.11 0.04 <0.001 0.81 0.04 <0.001 6.97 0.03 <0.001 
 Model 2 0.41 0.05 <0.001 0.92 0.04 <0.001 6.52 0.04 <0.001 
 Model 3 0.18 0.06 0.002 0.68 0.04 <0.001 6.44 0.10 <0.001 
Emergency 
Department          
 Model 1 0.38 0.06 <0.001 0.72 0.05 <0.001 4.05 0.05 <0.001 
 Model 2 0.31 0.06 <0.001 0.79 0.05 <0.001 3.74 0.05 <0.001 
 Model 3 0.01 0.08 0.884 0.42 0.05 <0.001 4.12 0.10 <0.001 
Inpatient          
 Model 1 0.78 0.07 <0.001 0.49 0.07 <0.001 6.09 0.06 <0.001 
 Model 2 0.69 0.09 <0.001 0.67 0.08 <0.001 5.26 0.06 <0.001 
 Model 3 0.45 0.11 <0.001 0.31 0.10 0.002 5.70 0.17 <0.001 
Physician          
 Model 1 0.27 0.02 <0.001 0.49 0.02 <0.001 4.82 0.02 <0.001 
 Model 2 0.18 0.03 <0.001 0.51 0.02 <0.001 4.54 0.02 <0.001 
 Model 3 -0.01 0.02 0.582 0.29 0.02 <0.001 4.32 0.04 <0.001 
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified 
between 2007 and 2014 and had enrollment between 2006 and 2015. These patients were between 28-63 years 
old, without cancer, had complete demographic information available, and had only one opioid prescription on 
the index date. Individual weights based on inverse probability of treatment weighting (IPTW) have been used 
for this analysis. Model 1 is only adjusted for time and chronic opioid therapy; Model 2 is also adjusted for 
number of other chronic conditions; Model 3 is also adjusted for number of other chronic conditions, sex, age, 
region, history of drug abuse, painful conditions, benzodiazepine use, non-opioid analgesic use, and number of 
unique medication classes.  
Abbreviations: COT- chronic opioid therapy; Wt- weighted; AOR- adjusted odds ratio; Rx- prescription; SE- 
semi-robust standard error 
Sig: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = * 
 
 
47 
 
Figure 3.1. Difference in average total expenditures (no prescription drug costs) between chronic 
opioid therapy (COT) and no COT transition using a counterfactual prediction technique 
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CHAPTER 4 
4 Identifying targeted continuing educational strategies to help community pharmacists 
implement naloxone/buprenorphine-related medications in community pharmacies: A 
state-wide survey among pharmacists 
4.1 Abstract 
Objective: To identify educational strategies related to opioids, buprenorphine products, and 
naloxone, for pharmacists, and to determine geographic locations to reduce the risk of opioid 
overdose in West Virginia (WV). Methods: A mixed-methods design included a prospective 
cross-sectional survey administered in two phases [in-person (n=157) and online (n=144)] to 
increase coverage of the whole state, then results were weighted based on a census of all 
pharmacists in WV. Educational strategies for community pharmacists (n=179) were identified 
with the Extended Parallel Process Model (EPPM), while educational objectives were based on 
attitudes, dispensing/stocking practices, and knowledge gaps about opioids, naloxone, and 
buprenorphine products. Qualitative responses (n=97) were also evaluated and themes were 
developed. Results: Most pharmacists perceived high risk of opioid misuse in their area and high 
perceived efficacy about naloxone as a treatment for opioid overdose, but many did not feel 
comfortable selling naloxone. Opioid attitudes significantly differed between pharmacists in 
different EPPM-assigned categories. Filling practices differed; 73% stocked 
buprenorphine/naloxone and only 58% stocked buprenorphine. Pharmacists with higher 
perceived efficacy of buprenorphine products were more likely to be willing to fill non-local 
prescriptions. County-level disparities between actual and perceived risk for opioid misuse were 
observed. In the qualitative evaluation, pharmacists listed many barriers to caring for patients 
prescribed opioids or buprenorphine products. Conclusion: By tailoring educational strategies 
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and objectives to pharmacists in specific geographic locations, more effective CPE can be 
delivered to community pharmacists in WV to improve access to naloxone and buprenorphine 
products as well as improve their understanding of addiction and psychosocial treatments. 
4.2 Introduction 
Opioids, both prescription and illicit, contribute to the vast majority of drug overdose 
deaths, and are the leading cause of unintentional death among adults in the United States 
(US).102 In 2015, West Virginia (WV) led the country with 35.5 deaths per 100,000 inhabitants – 
more than twice the national average.47 Adverse effects due to prescription opioids often result in 
increased emergency room visits, inpatient visits, and other healthcare utilization.2-5 Access to 
both naloxone and comprehensive opioid use disorder treatment programs is very limited in the 
US, especially in West Virginia (WV).103  
Opioid use disorder, one of the diagnoses with highest risk for opioid overdose, can be 
managed with combination of psychosocial and pharmacological treatments, including 
methadone, naltrexone, and buprenorphine-containing regimens.104,105 Also, unintentional opioid 
overdose deaths can be avoided with the use of naloxone.7,15,55,56 Naloxone has been approved in 
many forms (e.g. intranasal, intravenous) and can completely block or reverse the effects of 
opioid medications, including extreme drowsiness, slowed breathing, or loss of consciousness, 
and prevent death due to opioid overdose.55,56 Expanding access in the community to 
buprenorphine products and naloxone is part of a nation strategy for avoiding mortality due to 
opioid overdoses.54,104,106 
Naloxone delivery in a community needs a multipronged approach including two 
important system strategies as described in previous research.107 First, access to naloxone must 
be made available through state legislation and Boards of Pharmacy, promoted by departments of 
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public health, and covered by insurers.107 In states where naloxone is already available in 
community pharmacies, there is evidence of reduction in overdose related deaths.57 Second, 
pharmacists and pharmacy technicians need the training and motivation to support the 
implementation of increased naloxone availability in urban and rural settings.107   
Pharmacists working in community pharmacies are the most widely available healthcare 
professionals58 and the gatekeepers to prescription opioids as well as the medications used to 
treat opioid use disorder. However, pharmacists are currently under-utilized as stakeholders to 
affect change in the patients succumbing to adverse consequences of opioid abuse including drug 
overdoses and deaths.54 As providing naloxone within the community is a voluntary act, 
expanding capacity to provide such a service will require the buy-in from local pharmacists thus 
making an assessment of pharmacists’ perceptions and providing for their educational needs a 
critical component of the second strategy to increase naloxone delivery in the community.   
Buprenorphine products (buprenorphine/naloxone and buprenorphine single-ingredient 
products) are prescribed widely as part of a comprehensive treatment plan for use in patients 
with opioid use disorders.108 Access to these products has been limited by the quantity limits 
placed on the number of dosage units a wholesaler has to distribute to individual pharmacies,109 
and by pharmacists having mixed attitudes as to whether or not to stock or dispense these 
medications.104,110,111 The willingness to stock and dispense medications to treat opioid use 
disorder as well as educational strategies used to increase this willingness, can be assessed 
similarly to naloxone. 
Given the extent of the opioid crisis in WV, the state can be seen as a focal point needing 
evaluation regarding the capacity of community pharmacies to provide naloxone and other 
opioid-related medications due to its reliance on community pharmacies to provide access to 
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healthcare and its current high levels of opioid abuse and deaths.112 In our previous study of WV 
community pharmacists, opioid stocking was universal, stocking of buprenorphine products was 
less common, readiness to dispense naloxone was low, and general educational strategies were 
identified.110 To optimize the process of providing naloxone to the communities of WV requires 
an evaluation of the educational needs of pharmacists as well as their individual perceptions on 
opioid-related medication efficacy, naloxone efficacy, and willingness to stock naloxone and 
buprenorphine products. 
The Extended Parallel Process Model (EPPM), has been used to create public 
communication and education in order to increase awareness and create change to address 
important health issues by appealing to the individual’s desire to control either danger or 
fear.113,114 It has also been used to assign broad, educational strategies to pharmacists based on 
perceptions of efficacy and risk.110 The key EPPM constructs include perceived severity, 
perceived susceptibility, response efficacy, and self-efficacy.110,113-115 By assessing these four 
constructs in this study, pharmacists can be placed into one of four categories defined by the 
EPPM based on their perception of both the risk (High/Low) and efficacy (High/Low). Targeted 
education can be created for each of these four categories to effectively tailor and deliver the 
intervention to pharmacists throughout WV to have the greatest impact.  
4.3 Objective 
The objective of this study was to identify broad educational strategies and educational 
objectives related to opioids, buprenorphine products, and naloxone, for pharmacists, and to 
identify geographic locations to provide targeted continuing pharmacists education (CPE) events, 
using a state-wide, representative survey of pharmacists licensed and working in WV. 
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4.4 Methods 
Design/Data collection 
A prospective cross-sectional design with survey methodology was used to assess the 
educational needs of community pharmacists in WV. A 49-item data collection instrument which 
was previously created and validated in WV pharmacists110 was administered in two phases. In 
the first phase, the surveys (n=157) were collected at live CPE events with preliminary results, 
including validation of scales, as published previously.110 For the second phase, additional 
responses (n=144 complete responses) were collected online to increase coverage of pharmacists 
throughout the state. Pharmacists who were at any CPE event where surveys were collected were 
not eligible for the online survey. Both phases of data collection occurred between April 2016 
and April 2017.  
To ensure representativeness, a census of all pharmacists licensed and working in WV 
was collected. With the agreement of the West Virginia Board of Pharmacy (WVBOP), three 
researchers (JDT, XZ, and ND) collected demographic information [email, gender, date or birth, 
current status (active/inactive), and county of employer] of all pharmacists licensed and working 
in WV. This information was up-to-date as of the most recent license renewal in July 2016. This 
is the first time the effort has been made to determine which pharmacists work in WV, as 
opposed to those licensed in WV but working elsewhere. Email addresses were used to send the 
electronic version of the survey to pharmacists who did not attend a live CPE event earlier in the 
year using Qualtrics’s anonymous data collection option. The study, survey, and census data 
collection were approved by the West Virginia University Institutional Review Board. 
Measures 
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Components of the survey have been described, in detail, in our previous publication.110 
Other measures for this study not previously described are included below: 
EPPM Category (High Risk/High Efficacy; High Risk/Low Efficacy; Low Risk/High Efficacy; 
Low Risk/Low Efficacy): The main constructs used in the EPPM (1- severity, 2- susceptibility, 3- 
response efficacy, and 4- self-efficacy) were assessed with (1) opioid adverse event scale, (2) 
perceived misuse of opioids, (3) efficacy of naloxone to reverse an opioid overdose, and (4) 
ability to dispense naloxone at a community pharmacy, respectively. For the continuously-
measured constructs used to assess Risk (severity and susceptibility), the median score was used 
to categorize pharmacists (High or Low). For categorically-measured constructs (response 
efficacy and self-efficacy) a response of 4 or greater on a 5-point Likert-type scale which 
indicated “Agree” or “Strongly Agree” was used to categorize pharmacists based into High 
Efficacy or Low Efficacy groups. If a pharmacist had high in either severity/susceptibility or 
response efficacy/self-efficacy, they were considered as having a High Risk or High efficacy, 
respectively.  
Buprenorphine perceived efficacy scale consisted of three items adapted from the Clinicians’ 
Attitudes and beliefs about Opioids Survey’s (CAOS) perceived effectiveness subscale, for use 
with pharmacists.116 
Drug-overdose death rate (by county): To assess broader, county-level risk, the age-adjusted 
drug-overdose mortality rates for each county in WV102 were categorized as high (>30 per 
100,000 population) or low (≤30). 
Data analyses 
Census data from the WVBOP were manually entered into an Excel (Microsoft, 2016) 
spreadsheet by two of the researchers (JDT and XZ). For the electronic survey responses, 
 
 
54 
 
Qualtrics data output was imported into SPSS (v22, IBM, 2016) for cleaning and converted for 
use in SAS (v9.4, Cary, NC) for analysis. Principal component analysis (PCA) and Cronbach’s 
alpha was assessed for the buprenorphine efficacy scale. Principal component analysis (PCA) is 
a data reduction technique that selects a subset of variables based on correlation or covariance 
(validity). Cronbach’s alpha is a measure of internal consistency of the scale (reliability). 
Descriptive (e.g., frequencies, means, and standard deviations) and inferential statistics 
were used to describe the data from this cross-sectional research survey. Chi-square analysis 
were used to examine the differences in the community pharmacist subgroups based on the 
EPPM constructs, geography, and stocking/dispensing practices. If expected cell sizes were less 
than five for at least 20% of cells, exact statistics were assessed (e.g. Fisher’s Exact Test). All 
statistical analyses assumed a significance level of alpha = 0.05. The study data were analyzed 
using SAS (v9.4; Cary, NC). 
Sample weighting 
Ideally, the sample of pharmacists represents the population from which they were 
selected.  However, in our study, we observed significant differences in the age distribution of 
respondents and the WVBOP sampling frame data. There were 2,058 pharmacists licensed and 
working in WV, as of the most recent license renewal in July 2016.; 9.6% of the state 
pharmacists were in the age group 24-29 while 15.6% of the study sample was in that age group. 
Therefore, we created sampling  
 weights based on and age of pharmacists licensed and working in WV. These weights were 
calculated as inverse probability using the age distribution of the WVBOP sampling frame. 
However, results were presented both before and after applying individual weights.  
Qualitative Assessment 
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The open-ended items from the survey’s written responses were evaluated using 
qualitative methods. Each response was entered into ATLAS.ti (version 1.0.51), a program used 
for qualitative assessment and coding. Two researchers (JDT and XZ) reviewed the responses 
independently to identify codes for qualitative assessment. The codes were discussed and agreed 
upon through consensus with a third researcher (ND) serving as an arbitrator and reviewer. 
Codes were then assigned to the responses independently and agreed upon. The codes were 
grouped into themes which were developed using the Grounded Theory approach.117 
4.5 Results 
Overall, 301 pharmacists responded to the survey either in person or on-line, and Table 4.1 
compares the sample of survey respondents to the population of WV pharmacists.  There were 
172 community pharmacists who completed the survey.). Age-weighted and unweighted 
characteristics of responding pharmacists can be seen in Table 4.2, and the unweighted sample 
was mostly female (50.3%), first licensed after 1990 (66.9%), worked in a fulltime (76.0%) staff 
position (55.3%), in counties with drug-overdose death rates of ≤ 30 per 100,000 population.  
The descriptive information on the values of the constructs used in the EPPM (severity, 
susceptibility, response efficacy, and self-efficacy), opioid attitudes, naloxone attitudes, stocking 
practices, filling practices, and whether the respondent left information to be included in the 
qualitative assessment (56.2%) was provided in Table 4.2. Of note, pharmacists in WV believed 
that opioids are being over-prescribed in their county (82.7%), agreed that they are helping to 
curb opioid diversion by declining to fill some prescriptions for opioids (73.2%), but 41.5% 
agreed they were harming patients who have legitimate pain issues. There was a large gap in 
stocking practices between opioids and buprenorphine products with all community pharmacists 
stocking opioids, but only 73.0% stocked buprenorphine/naloxone and only 58.0% 
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buprenorphine. Along these same lines, more pharmacists would refuse to fill a prescription for 
an out of local area or out-of-state buprenorphine prescription (77.8% and 73.5%, respectively), 
compared to an opioid prescription (58.4% and 53.9%, respectively). Most pharmacists agreed 
that they are not adequately trained to use naloxone over the counter (67.6%). 
 The EPPM constructs, from which educational strategies are defined, were used to place 
pharmacists into four categories [High Risk/High Efficacy (HR/HE); High Risk/Low Efficacy 
(HR/LE); Low Risk/High Efficacy (LR/HE); or Low Risk/Low Efficacy (LR/LE)]. After 
weighting the sample for age, the majority of community pharmacists were categorized as having 
HR/HE (56.0%). The HR/HE group was more likely to be staff pharmacists or managers 
compared to owners (p<0.05). Opioid attitudes significantly differed between pharmacists in 
different EPPM-assigned categories as well. The HR/HE group was less likely to think chronic 
opioids were necessary for their chronic non-cancer pain patients (p<0.001), but were more 
likely to neither agree nor disagree that opioids were being prescribed in their county (p<0.01). 
Also, pharmacists in the HR/HE group were less likely to agree that letting patients purchase 
naloxone over the counter will increase opioid overdosing (p<0.05). Other comparisons can be 
seen in Table 4.3. 
 To identify educational objectives based on buprenorphine products, perceived efficacy 
and misuse of buprenorphine products were compared to county characteristics and 
stocking/dispensing practices of these products. The newly-validated three-item buprenorphine 
efficacy scale for pharmacists had all three items load on one component (>0.8), was reliable 
with a Cronbach’s α = 0.79, and had a mean of 7.88 (SD=2.72). Overall, WV pharmacists on 
average estimated that 30.7% of prescriptions for buprenorphine products were misused or 
abused. Lower perceived buprenorphine efficacy was associated with a lack of willingness to fill 
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a non-local (p<0.001) or out-of-state (p<0.01) prescription for those products. Perceived 
buprenorphine misuse was associated with declining a prescription for not being for a legitimate 
medical purpose (p<0.05). Other comparisons for buprenorphine constructs can be seen in Table 
4.4. 
 Qualitative responses were assessed for the 97 community pharmacists in WV who 
provided comments on the open-ended items. A common theme was that opioids are being 
overprescribed in general, and in their local areas. Another frequent theme was that there is a 
responsibility on the prescriber since pharmacists are not able to make opioid regimen changes. 
Table 4.5 has quotations from pharmacists used to categorize qualitative responses into themes 
relating to barriers to making available opioids, naloxone, or buprenorphine products. There 
were many reasons for refusing prescriptions that included need for education (e.g. “All 
healthcare providers need more education in handling patients with pain…”) and stigma towards 
patients (e.g. “…it’s very hard to determine who has a legitimate need due to the stigma of 
opioid use”). In addition to reasons for refusing to fill prescriptions, pharmacists expected 
buprenorphine regimens to be de-escalated regularly (e.g. “it is very rare that I see the 
[buprenorphine products] dose decreased”). 
4.6 Discussion 
The Extended Parallel Process Model can be used to help tailor educational strategies for 
pharmacists to improve access to naloxone and buprenorphine products as well as their 
understanding of addiction and psychosocial treatments. Although the majority of the 
respondents surveyed expressed concerns about opioid overuse in their counties, most of them 
were not adequately trained to dispense naloxone over the counter. There were significant 
differences in opioid, naloxone, and buprenorphine product attitudes among community 
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pharmacists, which can be targeted in different CPE events. Educational objectives can be 
determined based on the gaps in knowledge.  
Two components are needed to deliver effective CPE: educational materials developed 
based on need and target areas where an impact can be made. The EPPM has been used to 
identify board educational strategies for pharmacists, that takes into account their ability to be 
influenced by certain components of the EPPM (namely, affect and cognition).110,115 According 
to this conceptual framework, most of the respondents had High Risk and High Efficacy levels 
(HR/HE) and they will be responsive to a call to action and information on the infrastructure 
available to deliver naloxone through their community pharmacies.115 Whereas pharmacists with 
Low Efficacy or Low Risk, strategies will need to focus on their ability to act and their role to 
play, or the actual risk in their community of adverse consequences of opioids, respectively.110,115 
 Identifying counties to provide CPE can be based on the disparity between actual (based 
on drug death rate) and perceived risk. For example, based on our state-wide survey results, 
pharmacists in Raleigh County (7% of all pharmacists licensed and working in WV) were more 
likely to have a low perceived risk, but the actual drug-overdose death rate in the county was 
over 30 deaths per 100,000 population.102 This is one location where risk-based education can be 
emphasized, to have a greater impact. Alternatively, another county, Mingo County, has high 
actual risk and the pharmacists who responded indicated a high perceived risk, thus risk-based 
education118 might not be as impactful. 
For patients with chronic painful conditions or patients with opioid use disorders to have 
access to their medications, pharmacists working in community pharmacies must be willing to 
stock and fill those medications. Lower perceived efficacy or suspected misuse of these 
medications made it less likely that the pharmacist would either stock or fill prescriptions for 
 
 
59 
 
these products. To this point, quantitative results were reinforced by the qualitative responses 
provided by the pharmacists. Community pharmacists emphasized the need for increased 
education on pain management and effective communication between all stakeholders (patients, 
pharmacists, prescribers, and the government regulators).   
The availability of buprenorphine is a problem throughout the US, especially in WV. 
Only certain prescribers can write prescriptions for these medications, and patients seeking 
treatment for opioid use disorder far outpaces the number of spots available for treatment in 
high-quality centers.119 Buprenorphine products are also limited by wholesalers who report high 
use pharmacies and prescribers to the FDA and DEA.109 Due to the scarcity of these products, 
some patients must travel great distances to fill their legal prescription. Pharmacists can be 
compounding this problem because they are worried about out-of-state and out of local area 
prescriptions. Again, the qualitative responses reinforced the quantitative results, that 
pharmacists are worried about misuse and abuse of buprenorphine products. Many pharmacists 
noted that they expected buprenorphine regimens to have tight oversight with regular dose de-
escalation. The treatment paradigm for opioid use disorder is changing so that patients are treated 
as though they have a chronic illness.120 Some of these patients will have better outcomes in 
terms of recovery with fewer relapses if buprenorphine regimens are maintained long-term. 
Education for pharmacists that focuses on these use-cases can possibly decrease the perceived 
misuse and increase perceived efficacy of these products. 
Providing education on pain management, use of naloxone in the community, opioid use 
disorder, and how to improve communication with both prescribers and patients will be 
beneficial to pharmacists and patients seeking care. Education on addiction may help reduce 
stigma and increase a sense of the broad range of psychosocial and pharmacological treatment 
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options. Future research can focus on providing pharmacists with tailored education to reduce 
stigma and encourage participation to dispense buprenorphine and naloxone to help people 
suffering from opioid use disorder and potential drug overdose. These future studies can be 
guided by the Kirkpatrick model used to evaluate training programs.121 Using this model, four 
factors would be assessed throughout a follow-up period starting with reaction to the tailored 
intervention, then an evaluation of learning after the training program. Longer-term evaluations 
of tailored educational interventions would assess changes in behavior and impact to the 
community. 
This is the first study to identify targeted continuing educational intervention for 
community pharmacists based on the EPPM conceptual framework. These education 
components can be used to affect change in terms of availability of naloxone and buprenorphine 
products. There were many strengths to this study including the use of a population census of 
pharmacists licensed and working in WV to generalize the survey results for the entire state of 
WV. This study collected the first functional census of WV pharmacists to ensure state-wide 
representativeness of the findings.  Also, this population-based survey of pharmacists focused on 
currently under-utilized providers who can play a critical role in preventing opioid-related 
overdose and death.  This study had a few potential limitations. Surveys were collected over the 
period of one year, so pharmacists could have received education on naloxone through their 
employers or the state. However, current naloxone education in WV is not tailored to 
pharmacists and focuses on emergency administration. The surveys were collected via two 
modes of data collection, but the sample was assessed for representativeness and weighted based 
on age to mitigate this limitation. Survey research has certain potential limitations associated 
with the data collection process. The validity of the results may be affected by the usual 
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limitations of self-report questionnaires and thus may not fully reflect the respondents’ beliefs, 
attitudes, or actual practices. 
4.7 Conclusion 
West Virginia community pharmacists’ stocking and dispensing of naloxone and 
buprenorphine products are affected by their beliefs about efficacy, misuse, and abuse of these 
products. Most pharmacists felt unprepared to dispense naloxone over the counter. Using 
targeted educational strategies, locations, and objectives, more effective CPE can be delivered to 
community pharmacists in the state to improve access to critical, potentially life-saving, 
medications. 
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Table 4.1. Characteristics of the sample of survey respondents compared to the population of pharmacists licensed 
and working in West Virginia as of July 2016. 
  Sample Population 
All  n=301 Column % n=2,058 Column % 
Age (years)     
 24-29 47 15.61 197 9.57 
 30-34 46 15.28 319 15.50 
 35-39 40 13.29 290 14.09 
 40-44 29 9.63 302 14.67 
 45-49 28 9.30 251 12.20 
 50-54 29 9.63 190 9.23 
 55-59 28 9.30 186 9.04 
 60-64 24 7.97 170 8.26 
 65+ 22 7.31 153 7.43 
 Missing 8 2.66 -- -- 
Gender     
 Female 154 51.16 1,073 52.14 
 Male 146 48.50 985 47.86 
 Missing 1 0.33 -- -- 
Notes: Survey data was collected between April 2016 and April 2017 from pharmacists licensed and working in WV. Population 
data was collected from the WV Board of Pharmacy license renewal forms on site and is up-to-date as of July 2016. County-
level information was collected for both the sample and population, but placed in categories for display purposes.  
 
  
 
 
63 
 
Table 4.2. Description of the sample of community pharmacists licensed and working in WV that responded to 
the survey, weighted by age based on the state-wise census of pharmacists. 
All  n = 172 Wt. % 
Pharmacist and Workplace Characteristics 
Gender (n=171)    
 Female  86 51.6 
 Male  85 48.3 
Year first licensed    
 1980 and before  26 14.8 
 1981-1990  31 17.0 
 1991-2000  44 32.4 
 2001 and after  71 35.8 
Position (n=170)    
 Owner or Part owner  19 11.8 
 Management (including Pharmacist in Charge)  57 34.3 
 Staff  94 53.9 
Work schedule (n=171)    
 Fulltime  130 76.3 
 Part-time  41 23.7 
Region (US Congressional District) (n=170)  
 First (Northern)  69 39.5 
 Second (Central and Eastern)  52 32.8 
 Third (Southern)  49 27.7 
Drug-related deaths in county of workplace (n=170) 
 High (>30)  62 35.2 
 Low (≤30)  108 64.8 
EPPM Constructs (n=172) 
Severity: Opioid adverse event scale score 
   Mean = 23.1 SD = 3.5 
Susceptibility: Perceived misuse of opioids at community pharmacy 
   Mean = 29.5 SD = 24.5 
Response efficacy: Efficacy of naloxone 
 High  130  
 Low  42  
Self-efficacy: Dispense naloxone at community pharmacy 
 High  39  
 Low  133  
Opioid Attitudes 
Opioid perceived efficacy scale (n=168)  
   Mean = 14.9 SD = 3.5 
Taking opioids for long periods of time is necessary for many of my chronic 
non-cancer pain patients. (n=171)  
 Disagree  90 52.0 
 Neither  33 18.9 
 Agree  48 29.1 
Long-term use of opioids is overprescribed for patients with chronic non-cancer 
pain.  
 Disagree  8 5.0 
 Neither  11 6.7 
 Agree  153 88.3 
Continued 
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Table 4.2. Description of the sample of community pharmacists licensed and working in WV that responded to 
the survey, weighted by age based on the state-wise census of pharmacists. 
All  n = 172 Wt. % 
Some clinicians in my county prescribe opioids to their patients with chronic 
non-cancer pain for long periods of time too frequently.  
 Disagree  4 2.8 
 Neither  14 9.5 
 Agree  154 87.7 
Opioids are being overprescribed by practitioners in my county.  
 Disagree  9 5.6 
 Neither  19 11.7 
 Agree  144 82.7 
Pharmacists are curbing opioid diversion and/or abuse by declining to fill some 
prescriptions for opioids.  
 Disagree  20 11.7 
 Neither  26 15.1 
 Agree  126 73.2 
Pharmacists are harming some patients who have legitimate pain issues by 
declining to fill some prescriptions for opioids. (n=171)  
 Disagree  60 35.2 
 Neither  40 23.3 
 Agree  71 41.5 
Naloxone Attitudes 
Letting patients purchase naloxone over the counter will 
increase opioid overdosing. (n=171) 
 
  
 Disagree  53 29.1 
 Neither  51 30.3 
 Agree  67 40.6 
I do not believe that I am adequately trained in the use of 
naloxone over the counter. 
 
  
 Agree  114 67.6 
 Unsure  29 16.2 
 Disagree  29 16.2 
Stocking Practices 
Stock opioids (n=171)  
 Yes, stocked  171 100.0 
 Not stocked  0 0.0 
Stock buprenorphine/naloxone (n=171)  
 Yes, stocked  125 73.0 
 Not stocked  46 27.0 
Stock buprenorphine (n=170)  
 Yes, stocked  97 58.0 
 Not stocked  73 42.0 
Filling Practices 
Fill a non-local (outside a 20-mile radius of your pharmacy) prescription for opioid  
 Would not fill  97 58.4 
 Would fill  75 41.6 
Fill an out-of-state prescription for an opioid  
 Would not fill  94 53.9 
 Would fill  78 46.1 
Continued 
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Table 4.2. Description of the sample of community pharmacists licensed and working in WV that responded to 
the survey, weighted by age based on the state-wise census of pharmacists. 
All  n = 172 Wt. % 
Fill a non-local (outside a 20-mile radius of your pharmacy) prescription for 
buprenorphine/naloxone (n=166)  
 Would not fill  127 77.8 
 Would fill  39 22.2 
Fill an out-of-state prescription for a buprenorphine/naloxone (n=164)  
 Would not fill  122 73.5 
 Would fill  42 26.5 
Provided Qualitative Response 
Responded to at least one qualitative item    
 No  75 43.8 
 Yes  97 56.2 
Notes: This sample includes patients a survey of pharmacist licensed and working in West Virginia as of July 2016. Some 
categories were collapsed. Weighted N were rounded to nearest whole person. EPPM categories were created using 
unweighted measures of central tendency, so weighted results are not presented. 
Abbreviations: Wt. % = weighted percentage 
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Table 4.3. Extended Parallel Process Model (EPPM) categories for a sample of community pharmacists licensed 
and working in WV, weighted by age based on the state-wise census of pharmacists   
High Risk/ 
High Efficacy 
High Risk/  
Low Efficacy 
Low Risk/ 
High Efficacy 
Low Risk/ 
Low Efficacy 
 
  
Wt. n Wt. % Wt. n Wt. % Wt. n Wt. % Wt. n Wt. % Sig. 
All 100 56.0 31 17.4 37 20.6 11 6.0 
 
Pharmacist and Workplace Characteristics 
Gender 
         
 
Female 58 63.5 15 16.5 14 15.0 5 4.9 
 
 
Male 42 48.7 16 18.5 23 26.9 5 6.0 
 
Year first licensed         
 
 
1980 and before 17 65.6 2 7.6 6 23.0 1 3.8 
 
 
1981-1990 20 66.4 5 17.7 3 9.5 2 6.3 
 
 
1991-2000 27 46.6 13 23.2 14 24.1 3 6.0 
 
 
2001 and after 35 55.5 10 16.0 14 21.9 4 6.6 
 
Position         * 
 
Owner or Part 
owner 
6 27.1 3 15.3 9 40.9 3 16.7 
 
 
Management 
(including 
Pharmacist in 
Charge) 
40 66.8 10 16.0 8 12.8 3 4.4 
 
 
Staff 52 54.6 18 19.1 21 21.6 5 4.8 
 
Work schedule         
 
 
Fulltime 77 57.4 23 16.8 28 20.8 7 5.0 
 
 
Part-time 21 50.5 8 19.6 9 20.6 4 9.3 
 
Drug-related deaths in county of workplace 
      
 
High (>30) 31 50.2 14 23.1 12 19.2 5 7.5 
 
 
Low (≤30) 66 58.2 17 14.7 25 21.9 6 5.3 
 
Opioid Attitudes 
Taking opioids for long periods of time is necessary for many of my chronic non-cancer pain patients. ***  
Disagree 56 61.0 22 24.4 10 11.1 3 3.5 
 
 
Neither 20 59.2 2 6.6 7 21.2 4 13.0 
 
 
Agree 23 44.1 6 12.2 19 37.8 3 5.8 
 
Long-term use of opioids is overprescribed for patients with chronic non-cancer pain. 
 
** 
 
Disagree 3 32.5 0 0.0 6 67.5 0 0.0 
 
 
Neither 7 54.9 0 0.0 3 28.8 2 16.4 
 
 
Agree 91 57.3 31 19.6 28 17.6 9 5.5 
 
Opioids are being overprescribed by practitioners in my county. 
   
** 
 
Disagree 3 27.0 0 0.0 7 73.0 0 0.0 
 
 
Neither 16 77.9 3 12.5 2 9.6 0 0.0 
 
 
Agree 81 54.9 28 19.2 28 18.7 11 7.2 
 
Continued 
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Table 4.3. Extended Parallel Process Model (EPPM) categories for a sample of community pharmacists licensed 
and working in WV, weighted by age based on the state-wise census of pharmacists   
High Risk/ 
High Efficacy 
High Risk/  
Low Efficacy 
Low Risk/ 
High Efficacy 
Low Risk/ 
Low Efficacy 
 
  
Wt. n Wt. % Wt. n Wt. % Wt. n Wt. % Wt. n Wt. % Sig. 
All 100 56.0 31 17.4 37 20.6 11 6.0 
 
Pharmacists are curbing opioid diversion and/or abuse by declining to fill some prescriptions  
for opioids.  
Disagree 13 63.4 1 4.8 7 31.8 0 0.0 
 
 
Neither 14 51.9 5 17.1 4 15.6 4 15.4 
 
 
Agree 73 55.7 25 19.5 26 19.9 7 5.0 
 
Pharmacists are harming some patients who have legitimate pain issues by declining to fill some 
prescriptions for opioids.  
Disagree 37 60.0 13 21.2 9 14.6 3 4.2 
 
 
Neither 21 52.0 8 18.5 8 19.5 4 10.0 
 
 
Agree 41 56.1 10 13.9 18 24.7 4 5.3 
 
Naloxone Attitudes 
Letting patients purchase naloxone over the counter will increase opioid overdosing. 
 
*  
Disagree 32 61.6 5 9.8 14 27.5 0 1.2 
 
 
Neither 34 64.6 8 14.6 6 12.0 5 8.7 
 
 
Agree 32 44.9 18 25.3 16 22.3 5 7.6 
 
I do not believe that I am adequately trained in the use of naloxone over the counter. 
  
 
Agree 66 54.3 24 20.2 22 18.4 9 7.2 
 
 
Unsure 21 73.3 1 3.6 5 16.1 2 6.9 
 
 
Disagree 13 45.6 6 19.5 10 34.9 0 0.0 
 
Filling Practices 
Fill a non-local (outside a 20-mile radius of your pharmacy) prescription for opioid 
  
 
Will not fill 59 56.3 19 18.2 21 20.2 5 5.3 
 
 
Will fill 41 55.5 12 16.3 16 21.2 5 7.0 
 
Fill an out-of-state prescription for an opioid 
      
 
Will not fill 52 54.1 19 19.7 17 18.2 8 8.0 
 
 
Will fill 48 58.3 12 14.7 19 23.4 3 3.6 
 
Notes: This sample includes patients a survey of pharmacist licensed and working in West Virginia as of July 2016. Some 
categories were collapsed. Due to small expected cell sizes, exact tests were used to verify any significant results. Respondents in 
the sample with missing age values were given a weight of one for the weighted analysis. Weighted N were rounded to nearest 
whole person. 
Significance: 0 ≤ p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *, 0.05 ≤ p < 0.1 = + 
Abbreviations: Wt = weighted 
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Table 4.4. Perceived efficacy and misuse/abuse of buprenorphine prescription products by community factors and 
pharmacist practices in WV. 
  
Buprenorphine Efficacy  
Scale Score   
Estimated Misuse/Abuse of  
Buprenorphine Products (%)   
All 
Mean = 
7.88 
SD = 
2.72 
n = 
169 p value Sig 
Mean = 
30.74 
SD = 
31.56 
n = 
140 p value Sig 
Drug death in county   0.6314     0.0796 + 
 High 7.77 2.96 61   36.94 32.22 53   
 Low 7.98 2.59 106   27.28 30.77 86   
Stocking buprenorphine products  0.0794 +    0.1056  
 Yes 8.10 2.84 123   32.64 31.21 121   
 No 7.27 2.28 45   19.72 32.61 18   
Willing to fill non-local buprenorphine 
product <0.001 **    0.8613  
 Yes 9.15 2.70 39   30.44 28.02 39   
 No 7.49 2.61 124   31.48 33.00 99   
Willing to fill out of state buprenorphine 
product 0.0023 **    0.6765  
 Yes 9.00 2.80 41   29.71 29.91 42   
 No 7.51 2.62 120   32.17 32.41 95   
Declined prescription for buprenorphine 
for not being for a legitimate medical 
purpose 0.0635 +    0.0207 * 
 Yes 7.15 2.78 40   41.58 31.80 38   
 No 8.09 2.71 113   27.64 30.91 98   
Notes: This sample includes patients a survey of pharmacist licensed and working in West Virginia as of July 2016. Some categories 
were collapsed. 
Significance (Sig): 0 ≤ p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = *, 0.05 ≤ p < 0.1 = + 
Abbreviations: SD = Standard Deviation 
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Table 4.5. Barriers to the availability of opioid, naloxone, and buprenorphine product distribution through 
community pharmacies, among pharmacists licensed and working in WV.   
Example Quotations 
Reasons for refusing 
prescriptions 
  
  Out of state or 
local area 
“All pharmacists in our county are very picky about out of county or out of 
state controlled prescriptions.” 
 
“Concerned about not being able to track patients’ drug history across other 
states.” 
 
“…we don’t want to fill anymore opioids prescriptions from patients we have 
never filled before. Not that the prescriptions are fraudulent or have anything 
wrong with them.” 
 
  Need for 
effective 
communication 
“It is necessary though to form a strong patient-pharmacist relationship in 
order to ascertain any forms of abuse” 
 
“The problem is even irresponsible doctors have patients with legitimate 
pain.” 
 
“…the physician-patient medical relationship is impossible to prove from the 
pharmacy” 
 
  Need education 
on pain 
management 
“More educational programs are necessary for doctors” 
 
“Patients are not educated enough on how addictive opiates are” 
 
“All healthcare providers need more education in handling patients with 
pain…” 
 
 Stigma on 
patients 
“…it’s very hard to determine who has a legitimate need due to the stigma of 
opioid use.” 
 
“…I am now stereotyping every patient with an opioid prescription as a drug 
addict. I wish we didn’t even carry opioids at our pharmacy anymore.” 
 
Perceptions of abuse of 
buprenorphine products 
 
  No reduction in 
dose 
“It is very rare that I see the [buprenorphine products] dose decreased.” 
 
 “…patients are prescribed [buprenorphine products] without much oversight 
or without changes in dosages for long periods of time.” 
 
“… [prescribers] never reduce dose…” 
 
  Association with 
patient demeanor 
 “I feel that [buprenorphine product] is more abused and sold on the street 
than taken to treat opioid dependence.” 
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CHAPTER 5 
5 Discussion of findings and research implications 
5.1 Summary of Findings 
This dissertation had many unique components. This is the first study to identify incident 
COT in a nationally-representative sample of working-aged adults, who were initiated on opioid 
therapy. This is an important group to focus on because of the impact on productivity and their 
increased likelihood to receive opioid therapy when they experience pain.25 As a rate, we found 
that 13 out of 1000 patients with initial prescription of opioids transitioned to COT.  As 
demonstrated in this study, a smaller set of more easily assessed factors at initiation (duration of 
action, standardized dose, parent opioid, age, sex) can be used to gauge the risk of transition to 
COT. Our predictive models identified four leading predictors that increased the risk of transition 
to COT by at least four times.  These were: duration of action, type of parent opioids, drug use 
disorders, and painful conditions. 
The patients who do transition to COT have an increase in healthcare utilization and 
expenditures, as we found in the second aim of this study. Most trajectories of healthcare 
utilization and expenditures throughout the follow-up periods were different between COT and 
non-COT users. Any intervention focused on curbing transition to COT has the potential to 
prevent inpatient use and can lead to cost savings for the payer(s). 
Despite the consequences of transitioning to COT, the answer is not to withhold care. In 
the third aim of this study, all community pharmacies surveyed stocked opioid medications, but 
fewer stocked naloxone or buprenorphine products. The Extended Parallel Process Model can be 
used to help tailor educational strategies for pharmacists to improve access to naloxone and 
buprenorphine products as well as their understanding of addiction and psychosocial treatments. 
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The stocking and dispensing of naloxone and buprenorphine products by community pharmacists 
in WV are affected by their beliefs about efficacy, misuse, and abuse of these products. Using 
targeted educational strategies, locations, and objectives, more effective CPE can be delivered to 
community pharmacists in the state to improve care. 
5.2 Strengths and Limitations 
5.2.1 Strengths 
Strengths of this study include the availability of a nationally-representative sample of the 
US commercially-insured population, following individuals across multiple providers and 
settings, use of statistical and machine learning predictive methods, and availability of dates so 
that we could identify first, index opioid prescription. Also, this study assessed incident COT, 
which other studies have not distinguished from prevalent use of chronic or long-term opioid 
therapy. By using the NLM programs RxMix and RxNav to identify clinical drug components, 
the duration of action and parent opioid for each prescription could be identified, which allowed 
for more granular assessment of the opioid regimen using claims data. Finally, the data spanned 
many unique insurers and plan types, which allowed for the tracking of patients through time and 
to determine an opioid-free period of 12 months. 
The longitudinal design with repeated measures of utilization and expenditures for 
patients with and without transition to COT allowed for an assessment of baseline utilization and 
expenditures in the second aim. This allowed us to control for baseline profiles in terms of 
utilization, expenditures, and patient complexity. Furthermore, we applied robust statistical 
methods to control for observed selection bias. 
The conceptual framework (EPPM) was used to help tailor educational strategies for 
pharmacists to improve access to naloxone and buprenorphine products as well as their 
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understanding of addiction and psychosocial treatments These education components can be 
used to affect change in terms of availability of naloxone and buprenorphine products. This study 
collected the first functional census of WV pharmacists to ensure state-wide representativeness 
of the findings. Also, this population-based survey of pharmacists focused on currently under-
utilized providers who can play a critical role in preventing opioid-related overdose and death.   
5.2.2 Limitations 
The study also has some potential limitations. Prescription claims do not have 
information on variables such as pain, socio-economic status, social capital, medication beliefs, 
and response to pain treatment, which may affect transition to COT. Also, claims data allow for 
the identification of prescription medication, but not actual use of these medications. There are 
limitations of the predictive modeling results as well. The models were assessed in a unique 
subsample (testing data) of the overall sample. However, the validity of the model and its 
predicted probabilities will be more generalizable if applied to a different sample of patients, 
potentially from other commercial healthcare plans. The importance of factors could change, and 
even be improved if other types of information were added to the dataset (e.g. social 
determinants of health, medication use behaviors, prescriber characteristics).  
Surveys were collected over the period of one year, so pharmacists could have received 
education on naloxone through their employers or the state. However, current naloxone 
education in WV is not tailored to pharmacists and focuses on emergency administration. The 
surveys were collected via two modes of data collection, but the sample was assessed for 
representativeness and weighted based on age to mitigate this limitation. Survey research has 
certain potential limitations associated with the data collection process. The validity of the results 
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may be affected by the usual limitations of self-report questionnaires and thus may not fully 
reflect the respondents’ beliefs, attitudes, or actual practices. 
5.3 Conclusions and Implications of the study 
Our study findings suggest that an individual’s transition to COT can be predicted by 
information readily available in a clinical setting such as the initial opioid regimen 
characteristics, past history of drug use disorder, and painful conditions.  Predictive models can 
be used to aid clinician’s decision making; develop real-time predictions about future risk of 
transition to COT; influence policy, prescriber education, and prescription monitoring programs; 
and can applied to other patient populations. This transition to COT can also place a significant 
economic burden on payers and patients in terms of healthcare utilization and expenditures. 
Despite having similar baseline values, patients making the transition to COT had persistently 
high levels of utilization and expenditures even after 12 months following the transition to COT. 
The period of time after incident opioid prescription, but before COT, is an important time for 
intervention for payers and clinicians. 
Providing care for patients using, misusing, or even abusing opioid medications can be 
difficult, especially in rural states throughout the US. WV community pharmacists’ stocking and 
dispensing of naloxone and buprenorphine products are affected by their beliefs about efficacy, 
misuse, and abuse of these products. Most pharmacists felt unprepared to dispense naloxone over 
the counter. Using targeted educational strategies, locations, and objectives, more effective CPE 
can be delivered to community pharmacists in the state to improve access to critical, potentially 
life-saving, medications. 
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7 Appendices 
7.1 Supplemental Information- Chapter 2: Predictors of transitioning to incident chronic opioid therapy among working-
aged adults 
Supplemental Table 7.1.1. Logistic regression with adjusted odds ratio (AOR) and 95% confidence interval (95%CI) for patients with incident opioid use by transition to 
chronic opioid therapy after first opioid prescription, using QuintilesIMS Real-World Data Adjudicated Claims - US, 2006-2015  
Model 1 in  
Training/Validation subsample 
Model 1 in  
Test subsample 
Fully-adjusted model in 
Training/ Validation subsample 
Fully-adjusted model in Test 
subsample  
AOR 95% CI Sig  AOR 95% CI Sig  AOR 95%CI Sig  AOR 95% CI Sig 
Age (continuous) 1.02 [1.02,1.02] ***  1.02 [1.02,1.03] ***  1.02 [1.01,1.02] ***  1.02 [1.01,1.03] *** 
Male vs. Female 1.45 [1.37,1.53] ***  1.43 [1.27,1.60] ***  1.50 [1.41,1.59] ***  1.46 [1.30,1.65] *** 
Highly likely chronic pain 
vs. None 
5.98 [5.01,7.11] ***  5.91 [4.18,8.20] ***  5.59 [4.68,6.66] ***  5.47 [3.89,7.68] *** 
Likely chronic pain vs. 
None 
2.15 [2.02,2.27] ***  2.08 [1.84,2.34] ***  2.08 [1.96,2.21] ***  2.02 [1.79,2.28] *** 
Arthritis vs. None 1.83 [1.68,1.98] ***  1.92 [1.63,2.25] ***  1.78 [1.64,1.93] ***  1.86 [1.58,2.20] *** 
Hydrocodone vs. Codeine 2.19 [1.87,2.58] ***  2.04 [1.49,2.87] ***  2.15 [1.83,2.52] ***  1.97 [1.42,2.73] *** 
Oxycodone vs. Codeine 2.52 [2.13,3.01] ***  2.70 [1.92,3.90] ***  2.53 [2.13,3.02] ***  2.67 [1.87,3.81] *** 
Tramadol vs. Codeine 7.03 [5.99,8.31] ***  7.59 [5.53,10.74] ***  6.79 [5.77,8.01] ***  7.26 [5.20,10.13] *** 
All other opioids vs. 
Codeine 
6.03 [4.68,7.75] ***  5.71 [3.38,9.59] ***  5.89 [4.57,7.60] ***  5.64 [3.34,9.53] *** 
Long-acting vs. Immediate 
release 
16.01 [13.17,19.42] ***  12.43 [8.13,18.83] ***  16.08 [13.21,19.57] ***  12.28 [8.06,18.72] *** 
Moderate vs. Low dose† 0.52 [0.47,0.57] ***  0.45 [0.37,0.55] ***  0.52 [0.47,0.57] ***  0.45 [0.37,0.54] *** 
High vs. Low dose† 0.52 [0.41,0.65] ***  0.71 [0.47,1.05]   0.52 [0.41,0.65] ***  0.68 [0.45,1.02]  
Very high vs. Low dose† 1.77 [1.40,2.22] ***  1.27 [0.73,2.08]   1.72 [1.36,2.17] ***  1.24 [0.74,2.08]  
Benzodiazepine 
prescription vs. None 
2.06 [1.90,2.22] ***  1.99 [1.69,2.33] ***  1.82 [1.67,1.97] ***  1.82 [1.54,2.16] *** 
Drug use disorder 
diagnosis vs. None 
8.17 [6.75,9.83] ***  4.96 [3.13,7.58] ***  6.32 [5.17,7.73] ***  4.02 [2.53,6.40] *** 
Self vs. Spouse --    --    0.96 [0.88,1.05]   0.84 [0.71,1.01]  
Unknown vs. Spouse --    --    1.30 [1.19,1.42] ***  1.19 [1.00,1.43]  
Continued                
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Other vs. Spouse --    --    0.82 [0.70,0.97] *  0.93 [0.67,1.28]  
PPO vs. HMO --    --    1.06 [0.96,1.16]   1.20 [0.99,1.46]  
Other‡ vs. HMO --    --    0.86 [0.77,0.96] **  1.06 [0.84,1.34]  
Midwest vs. East --    --    1.13 [1.03,1.24] **  1.28 [1.06,1.55] ** 
South vs. East --    --    1.21 [1.11,1.32] ***  1.31 [1.08,1.58] ** 
West vs. East --    --    1.02 [0.90,1.15]   1.28 [0.99,1.64]  
Cardio-metabolic condition 
vs. None 
--    --    1.17 [1.10,1.25] ***  0.90 [0.79,1.03]  
Mental illness vs. None --    --    1.34 [1.25,1.45] ***  0.78 [0.67,0.91] ** 
Asthma vs. None --    --    0.87 [0.76,1.00] *  0.85 [0.64,1.13]  
COPD vs. None --    --    1.24 [0.92,1.67]   1.66 [0.92,3.02]  
Dementia vs. None --    --    1.33 [0.84,2.11]   1.75 [0.73,4.17]  
Hepatitis vs. None --    --    1.55 [1.18,2.04] **  1.94 [1.19,3.15] ** 
Osteoporosis vs. None --    --    1.44 [1.14,1.83] **  1.04 [0.59,1.83]  
Tobacco vs. None --    --    1.45 [1.29,1.64] ***  1.34 [1.04,1.73] * 
Any alcohol abuse vs. None --    --    0.93 [0.73,1.18]   0.78 [0.45,1.34]  
Acute pain condition vs. 
None 
--    --    0.86 [0.67,1.10]   0.95 [0.59,1.53]  
Stimulant prescription vs. 
None 
--    --    1.65 [1.40,1.95] ***  1.33 [0.93,1.91]  
Non-opioid analgesic vs. 
None 
--    --    1.06 [0.99,1.13]   1.14 [1.00,1.29] * 
Polypharmacy vs. None --    --    1.09 [1.02,1.17] *  1.03 [0.90,1.19]  
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified between 2007 and 2015 and had enrollment between 
2006-2015. These patients were between 28-63 years old, without cancer, had complete demographic information available, and had only one opioid prescription on the 
index date. Due to data use requirements, some categories were collapsed. These include insurance plan type and other opioids. 
†: Doses of opioids were converted to a standardized dose (milligrams of morphine equivalent) using the Centers for Medicare and Medicaid Services conversion table. 
‡: Other insurance types included fee-for-service, health savings account, and indemnity. 
Significance: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = * 
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Supplemental Figure 7.1.1: Receiver operator characteristic (ROC) curves for Model 1 (orange, 
AUC = 0.767) and Fully Adjusted Model 2 (purple, AUC = 0.778) using the training/validation 
subsamples 
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Supplemental Figure 7.1.2. Receiver operator characteristic (ROC) curves for Model 1 using 
the training/validation subsample (black, AUC = 0.767) and Model 1 using the test subsample 
(green, AUC = 0.776). 
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7.2 Supplemental Information- Chapter 3: Increased healthcare utilization and 
expenditures associated with transition to chronic opioid therapy 
 
  
Supplemental Table 7.2.1. 
Patient characteristics before and after applying inverse probability of treatment weighting (IPTW) for patients with 
incident opioid use by transition to chronic opioid therapy (COT) after first opioid prescription, 
QuintilesIMS Real-World Data Adjudicated Claims Database - US, 2006-2015 
  Before IPTW After IPTW  
All  COT No COT    COT No COT    
  
n= 
3,776 
% 
n = 
16,425 
% 
Chi-
square 
p-value Sig. Wt. % Wt. % 
Chi-
square 
p-value Sig. 
Sex     29.49 <0.001 ***   1.18 0.277  
 Male 2,000 53.0 7,895 48.1    49.8 49.0    
 Female 1,776 47.0 8,530 51.9    50.2 51.0    
Age     307.36 <0.001 ***   7.61 0.055  
 
28-34 
years 305 8.1 2,522 15.4    12.8 13.9    
 
35-44 
years 757 20.0 4,402 26.8    25.1 25.5    
 
45-54 
years 1,377 36.5 5,402 32.9    34.0 33.6    
 
55-63 
years 1,337 35.4 4,099 25.0    28.2 27.0    
Region     30.18 <0.001 ***   1.80 0.614  
 East 580 15.4 2,991 18.2    17.9 17.7    
 Midwest 1,290 34.2 5,478 33.4    34.3 33.6    
 South 1,642 43.5 6,587 40.1    40.0 40.7    
 West 264 7.0 1,369 8.3    7.8 8.1    
Highly likely chronic pain condition  301.41 <0.001 ***   0.02 0.890  
 Yes 112 3.0 41 0.2    0.8 0.8    
 No 3,664 97.0 16,384 99.8    99.2 99.2    
Likely chronic pain condition  938.71 <0.001 ***   0.88 0.347  
 Yes 2,064 54.7 4,693 28.6    34.1 33.5    
 No 1,712 45.3 11,732 71.4    65.9 66.5    
Note: This sample includes patients from QuintilesIMS RWD Adjudicated Claims – US, which were identified between 2007 and 
2014 and had enrollment between 2006 and 2015. These patients were between 28-63 years old, without cancer, had complete 
demographic information available, and had only one opioid prescription on the index date. Individual weights based on IPTW have 
been used for this analysis.  
Abbreviations: COT- chronic opioid therapy; Wt- weighted 
Sig: 0 < p < 0.001 = ***, 0.001 ≤ p 0.01 = **, 0.01 ≤ p < 0.05 = * 
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Supplemental Figure 7.2.1. Difference in unweighted average expenditures between chronic 
opioid therapy (COT) and no COT transition for total (no prescription drug), emergency 
department (ED), inpatient (IP), and physician costs. 
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